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Abstract 
Thalassemia is a heterogeneous group of genetic disorders of hemoglobin (Hb) synthesis, all 
of which result from reduced rate of production of one or more of the globin chains of Hb.  
The outcome of the disease depends on the severity of the mutation and the companion of 
other external modifiers that determine the clinical picture of the patient.  Thus, thalassemia 
is classified clinically into three major subclasses, thalassemia major (TM), thalassemia mi-
nor or trait and thalassemia intermedia (TI).  TI is most commonly caused by genetic defects 
in one or two of the globin genes: β, α or γ-globin gene.  Thalassemic patients suffer from 
many clinical complications that affect most body organs including severe bone deformities 
and hepatosplenomegaly. Several complications that were identified in thalassemic patients 
have been noticed to be unique to thalassemia intermedia over β thalassemia major.  Among 
these complications is the tendency of those patients toward forming venous thromboem-
bolic complications, cerebral, pulmonary or deep vein thrombosis in any other body site. 
This study aimed to determine thrombotic genetic mutations in a cohort of TI patients from 
West Bank region, Palestine that may increase the risk of developing thrombotic manifesta-
tions in these patients.  For this purpose, four thrombotic mutations were investigated: FV 
Leiden (G1691A), FII (G20210A), MTHFR (C677T) and platelet GP β3 (T1565C) muta-
tions/polymorphisms.   
Eighty-two TI patients, from the West Bank covering all thalassemia care centers in the West 
Bank region, were included in the study.  A matched group of non-anemic normal subjects 
were used as a control group.  Samples were tested for the presence of the four thrombotic 
mutations using RFLP-PCR, and results were analyzed by the chi-square at α (0.05).  
The study showed a gradual increase in the incidence of reporting of TI cases from north to 
south; with the lowest incidence reported in Jenin (5 cases) and the highest in Hebron (65 
cases).  The rate of thrombotic manifestation incidences among TI patients was found to be 
(3.7%).  Molecular testing of the thrombogenic mutations/polymorphisms revealed that 
1.3% of the TI patients were heterozygous and 2.5% were homozygous for the FII 
(G20210A) mutation.  According to FVL 19.5% of the patients were heterozygous and no 
homozygous cases were detected.  The highest incidence among the four polymorphisms 
was the MTHFR (C677T); where 39% of the patients showed heterozygosity for the poly-
morphism, and 6.1% were homozygous.  For the platelet GP β3 (T1565C) polymorphism 
9.8% of the patients were heterozygous and 1.2% were homozygous.  Chi-square analysis 
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revealed no statistically significant difference in the frequency of all four mutations/poly-
morphisms analyzed among the TI patients compared to normal control subjects.  However, 
such thrombotic genetic defects when combined with acquired thrombotic risk factors may 
contribute to the hypercoagulable state in TI patients, as illustrated in three patients among 
the study samples.  Furthermore, our results showed a substantial lower frequency of FII 
G20210A polymorphism and higher frequency of MTHFR C677T mutations among Pales-
tinians compared to previous reports.   
In conclusion, no statistical difference was observed in the frequency of the four thrombotic 
genetic defects investigated in this study between TI patients and normal control subjects. 
However, further investigations of TI patients for other thrombotic genetic defects may help 
to assess their contribution to the hypercoagulable state in such patients.  
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Definitions 
Beta-thalassemia: (β-thalassemia) are a group of inherited blood disorders caused by re-
duced or absent synthesis of the beta chains of hemoglobin resulting in variable phenotypes 
ranging from severe anemia to clinically asymptomatic. 
Deep vein thrombosis, or deep venous thrombosis, (DVT): is the formation of a blood clot 
(thrombus) in a deep vein, predominantly in the legs.  Non-specific signs may include pain, 
swelling, redness, warmness, and engorged superficial veins. 
Embolus: a freely travelling thrombus in the blood vessels. 
Hemorrhage: is the loss of blood from the circulatory system, which can occur internally 
or externally. 
Hemostasis: is a process that causes bleeding to stop, and retains blood within a damaged 
blood vessel and initiates wound healing.  
Infarction: death of an organ due to a blockage of the main nourishing artery of an organ 
because of hypoxia. 
Thalassemia: is inherited autosomal recessive blood disorders that originated in the Medi-
terranean region. 
Thrombosis: (Greek: θρόμβωσις) is the formation of a blood clot (thrombus; Greek: 
θρόμβος) inside a blood vessel, obstructing the flow of blood through the circulatory system. 
Thromboembolism: is thrombotic complications that occur due to an embolus, or emboli, 
and includes DVT and PE.  
Thrombus: a blood clot that is formed by aggregation of platelets and clotting factors. 
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Abbreviations 
ADP: Adenosine Di-phosphate 
APC: Activated Protein C 
 APCR: Activated Protein C Resistance 
APTT: Activated Partial Thromboplastin Time 
AT: Anti-thrombin 
DHF: Dihydrofolate 
DIC: Disseminated Intravascular Coagulation / Coagulopathy  
DVT: Deep Vein Thrombosis 
EPCR: Endothelial Protein C Receptor 
FII: Factor two 
FIX: Factor nine 
FV: Factor five 
FVa: Factor five activated 
FVII: Factor seven 
FVIII: Factor eight 
FX: Factor ten 
FXI: Factor eleven 
FXII: Factor twelve 
FV Leiden: Factor five Leiden 
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GP αIIβ3: Glycoprotein alpha-2 beta-3 
HA: Hemolytic Anemia  
Hb A: Hemoglobin A 
Hb A2: Hemoglobin A2 
Hb E: Hemoglobin E 
Hb F: Hemoglobin F / Fetal Hemoglobin 
HPFH: Hereditary Persistence of Fetal Hemoglobin 
HPVR: Hyper variable Region 
MRI: Magnetic Resonance Imaging 
MTHFR: Methylenetetrahydrofolate reductase 
NATP: Neonatal Alloimmune Thrombocytopenic Purpura. 
PAI: Plasminogen-Activator Inhibitor 
PCI: Protein C Inhibitor 
PCR: Polymerase Chain Reaction 
PE: Pulmonary embolism 
PEA: Phosphatidylethanolamine 
PF3: Platelet Factor 3 
PS: Phosphatidylserine  
PTP: Postransfusion Purpura 
RBC: Red Blood Cell 
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RFLP-PCR: Restriction Fragment Length Polymorphism-Polymerase Chain Reaction 
SAM: S-Adenosyl methionine 
TAFI: Thrombin-Activatable Fibrinolysis Inhibitor 
TFPI: Tissue Factor Pathway Inhibitor 
TI: Thalassemia Intermedia 
TPFS: Thalassemia Patient’s Friends Society 
VTE: Venous Thromboembolism 
β-TM: Beta Thalassemia Major 
  
 6 
 
 
 
 
 
 
 
 
Chapter One: Introduction 
_______________________________________________________________________ 
1 Introduction 
Since the first description of Thalassemia in five children presented with microcytic hypo-
chromic anemia, splenomegaly and bone deformities by Cooley and Lee in 1925 several 
studies were conducted in order to investigate the complications of this disease either by 
testing the etiology of the disease or by observing its clinical complications involving blood 
cells and other body systems that could be involved in the “thalassemia syndrome” (Cohen 
et al., 2004; Weatherall and Clegg, 2008). 
By the 1940s, the genetic characteristics of the disease were understood; and it was recog-
nized that the first identified cases were homozygotes for the autosomal disease, which was 
called thalassemia major, while the heterozygous, or the carrier state, which was associated 
with much milder, or clinically asymptomatic cases, was termed as thalassemia minor or 
minima.  Later on, a clinically significant, but not as severe as the major state, with a broad 
spectrum of symptoms where named thalassemia intermedia (Weatherall, 2006). 
Thalassemia is clinically heterogeneous and patients usually show diverse spectrum of clin-
ical symptoms that presents primarily with hematologic disorders (e.g. hemolytic anemia).  
If not properly treated, the condition exacerbates and disseminates to affect almost every 
organ in the body including bones, the skeletal system, the endocrine system, spleen, liver, 
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lungs, auditory system and cardiovascular system.  Thalassemia can also cause disturbances 
in the hemostatic system leading to thrombosis or infarction either in veins or arteries (Rund 
and Rachmilewitz, 2005).  
This study focuses on the hypercoagulable state and its complications in thalassemia inter-
media patients and detection of the genetic risk factors that were proven to be associated 
with thromboembolic disorders.  
1.1 Thrombosis and thrombophilia 
There is a delicate balance between the prohemorrhagic state and the prothrombotic state.  
However, the hemostatic system is highly regulated, and formation of a blood clot (or throm-
bus) is a very complicated.  A blood clot is composed of platelets consolidated with fibrin 
mesh; this agglomeration is usually formed as a response of the body to an incision or injury 
in a blood vessel.  This could arise in any blood vessel throughout the whole circulatory 
system.  Thus, platelets with many plasma proteins and the endothelium that lines blood 
vessels integrate together in order to prevent blood loss, due to hemorrhage; which could be 
either external or internal, and maintain intact vessels in a process called hemostasis (Furie 
and Furie, 2008).     
The hemostatic system is a meticulously controlled process involving six major regulatory 
systems:  (1) Platelets; which are subcellular fragments that form the primary plug and act 
as the bench plate that provide several factors and proteins and many hemostatic reactions 
are executed on.  (2) The vascular endothelium, which is termed to be non-wettable; that 
prevents blood loss through its tight endothelial cell-to-cell adhesion and repels any adhesion 
of platelets or coagulation factors.  (3) The procoagulant plasma proteins (i.e. the coagulation 
factors); act towards the formation of the fibrin mesh, which intensifies the primary plug 
formed by the platelets, through a set of successive steps which is triggered by certain stimuli 
to prevent bleeding or blood leakage from blood vessels.  (4) The natural anticoagulant pro-
teins (e.g. protein C and protein S) which counteract the action of the coagulation system by 
inhibiting the formation of a clot.  (5) The fibrinolytic proteins, which lyse the fibrin clot.  
(6) The antifibrinolytic proteins, which stops the action of the fibrinolytic system.  Each of 
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these six hemostatic components must be present in fully functional state, in adequate quan-
tity, and at the proper location to prevent excessive blood loss after vascular trauma and, at 
the same time, to prevent pathologic thrombosis (Brummel-Ziedins et al., 2004). 
Thrombophilia is not a disease per se; it is, rather, a term that expresses the tendency of a 
person towards developing thrombosis.  It is not an expectation of possibility of forming 
thrombosis, since developing thrombosis is a multifunctional process, but it determines the 
increased likelihood of developing thrombosis (Bertina and Rosendaal, 1998; Martinelli et 
al., 1998). 
The majority of the thrombophilic manifestations include venous thrombosis, or thrombo-
embolism (VTE), but the minority of cases develop arterial thrombosis; especially if vascu-
lar defects were accompanied (Heit, 2007).  Other less frequent cases present with visceral 
or cerebral vein thrombosis, second- or third- trimester pregnancy loss, severe preeclampsia 
and recurrent fetal loss and some complications of pregnancy (e.g., intrauterine growth re-
striction, stillbirth, placental abruption), purpura fulminans (neonatalis or adult), superficial 
or deep vein thrombosis (DVT), pulmonary embolism (PE), warfarin-induced skin necrosis, 
arterial thrombosis (e.g., stroke or acute myocardial infarction), thrombosis in unusual ve-
nous circulations (e.g., cerebral, hepatic, mesenteric, and renal veins; arm, portal, and ovar-
ian veins; retinal vein or artery) and many others (Heit, 2007). 
1.1.1. Risk factors of thrombophilia: 
Thrombosis is believed to develop because of combinations of several factors and defects 
together which result in accumulation of a clot at some site in a blood vessel, which was 
favored due to some reasons.  The majority of these risk factors either enhances procoagulant 
reactions or inhibits anticoagulant mechanisms and results in a hypercoagulable state 
(Dahlback, 2008b; Rosendaal, 1999a, b; Tripodi, 2003). 
The first suggestions of the existence of risk factors for thrombophilia were set in 1854 when 
Rudolph Virchow, a German pathologist, proposed that thrombosis results from three inter-
related factors; (1) decreased blood flow (venous stasis), (2) inflammation of the blood ves-
sels (vascular endothelial injury) and (3) intrinsic alterations in the nature of the blood itself.  
These factors were known as Virchow's triad (Kitchens, 1985; Seligsohn and Lubetsky, 
2001). 
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Most of the patients with thrombosis were noticed to share variety behaviors, which include some 
living habits, medications and clinical states (Dahlback, 2008b).  These non- genetic risk factors were 
indicated as environmental or acquired; since, no obvious genetic defect could be determined.  Those 
risk factors include prolonged immobilization, surgery, malignant diseases, inflammatory conditions, 
trauma, use of oral contraceptives, hormone replacement, pregnancy/puerperium, the presence of 
anti-phospholipid antibodies, previous history of thrombosis and advanced age  (Bertina, 2001; 
Dahlback, 2008b).  Those mentioned factors, and many others, have been recognized as risk factors 
for venous thrombosis (Table 1.1). 
 
Table 1.1: Genetic and acquired risk factors for venous thrombosis. 
        (Rosendaal, 1997) 
Acquired Inherited Mixed 
Increase in Age Factor V Leiden  Hyperhomocysteinemia 
Obesity Factor II (G20210A) High factor VIII levels 
Smoking Antithrombin deficiency Hyperfibrinogenemia 
Long flights Protein C deficiency  
Previous thrombosis Protein S deficiency  
Pregnancy and puerperium Dysfibrinogenemia  
Oral contraceptives   
Hormonal replacement therapy   
Immobilization   
Major surgery   
Orthopedic surgery   
Malignancy   
Myeloproliferative disorders   
Polycythemia vera   
Antiphosphohpid syndromes   
Arteriosclerosis   
Cardiovascular disease   
APCR * unrelated to factor V Leiden   
 APCR; Activated Protein C Resistance 
 
Splenectomy was noticed to be associated with the evolution of thrombosis; this was at-
tributed to the evolution of high numbers of platelets after splenectomy and having abnormal 
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forms of RBCs circulating in the blood stream (Cappellini et al., 2005; Cappellini et al., 
2000; Eldor and Rachmilewitz, 2002).  On the other hand, frequent transfusions were noticed 
to decrease the chance to have thrombosis for splenectomized patients (Cappellini et al., 
2000). 
Some studies indicated that prothrombotic genetic factors might interact with acquired ones 
(e.g. smoking) by modifying the stroke phenotype and affecting midterm survival (Oksala 
et al., 2007). 
1.1.1.1. Coagulation factors as risk factors for thrombophilia: 
Plasma level of several coagulation factors seems to have an impact on the tendency for 
thrombophilia.  For example, hyperprothrombinemia is one of the known risk factors for 
thrombophilia, and the identification of a point mutation in the 3ʹ untranslated region of the 
gene that leads to over production of prothrombin confirmed the  findings (Poort et al., 1996).  
Similarly, Hyperfibrinogenemia is another considered factor that correlates with thrombo-
philia (Kamphuisen et al., 1999; Koster et al., 1994).  Also, deficiencies of protein C, protein 
S and anti-thrombin were listed among the risk factors of thrombophilia (Dahlback, 2000; 
Nicolaes and Dahlback, 2002), with over 100 different mutations have been identified (Ta-
ble 1.2) (Seligsohn and Lubetsky, 2001). 
High level of FVIII is one of the strongly believed risk factors for genetic thrombosis, ac-
cording to studies that reported Familial clustering of high factor VIII levels in patients with 
venous thromboembolism (Kamphuisen et al., 2000a; Schambeck et al., 2001), but nobody 
succeeded to identify any polymorphism in the FVIII gene that is responsible for overex-
pression of this gene (Kamphuisen et al., 2001; Mansvelt et al., 1998).   
FV is homologous to FVIII; both are activated by thrombin, and are inhibited by activated 
protein C (APC), and they are cofactors for vital steps in the coagulation cascade, moreover, 
one could conclude that low levels of FV may have an impact in VTE since it acts as a 
cofactor for APC in the inhibition of FVIII.  But no evidence was noticed to correlate neither 
elevation nor reduction of FV with VTE except the in the case of APC resistance by Factor 
V Leiden (FVL) (Kamphuisen et al., 2000b).   
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It was early, proposed that FXI activation is done only by FXIIa.  This belief was disproved 
afterwards (Gailani and Broze, 1991; Naito and Fujikawa, 1991).  Levels of FXI is now 
known to be enhanced by elevated levels of thrombin and down regulation of fibrinolysis by 
the action of thrombin activatable fibrinolysis inhibitor (TAFI) (Von dem Borne et al., 1997).  
So, high levels of FXI is strongly advised to be considered as venous thromboimbolism 
(VTE) risk factor (Meijers et al., 2000; Tripodi, 2003).  Similarly, high levels of FIX could 
play a role in VTE as FIX is the main member of the tenase complex; a key step in the 
coagulation cascade (Tripodi, 2003; van Hylckama Vlieg et al., 2000).   
On the other hand, there is a big debate about the association between FXII deficiency and 
developing of VTE; where many researches tried to connect the presence of low levels or 
low activity percentage of FXII with VTE comparing diseased individuals with healthy ones 
using statistical analysis for these theories.  Some results showed positive relationship be-
tween  FXII deficiency and developing of VTE (Halbmayer et al., 1992), others showed no 
strong evidence for this relationship (Von Kanel et al., 1992), that’s why the role of FXII 
deficiency is still not considered as a risk factor for thrombophilia and many articles reject 
the role of FXII deficiency as a risk factors for VTE (Tripodi, 2003).   
Also, confusing results were obtained while studying FVII, FX and FXIII as risk factors for 
thrombosis, and they are still not considered as risk factors for VTE (Balogh et al., 2000; de 
Visser et al., 2001; Koster et al., 1994; Tripodi, 2003).  
1.1.1.2. Hereditary thrombophilia, a historical background: 
The first suggestions of hereditary thrombophilia were set in 1965 by Egeberg and Beck; 
where the former noticed recurrent venous thrombosis in a family whom was diagnosed to 
have antithrombin deficiency, which is inherited in an autosomal dominant manner, and the 
latter mentioned a hereditary thrombophilia due to inherited  dysfibrinogenemia (Beck et al., 
1965; Egeberg, 1965).  
In 1981, Griffin and colleagues correlated heterozygous protein C deficiency and venous 
thrombosis in young adults (Griffin et al., 1981).  In 1984, many reports were published 
showing that thrombosis correlates with protein S deficiency (Berman et al., 1986; Schwarz 
et al., 1984). 
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A critical finding made by Dahlback and coworkers in 1993 showed that venous thrombosis 
is often associated with hereditary resistance to activated protein C (APC) (Dahlback et al., 
1993; Svensson and Dahlback, 1994).  In 1994, several research labs indicated that resistance 
to APC could be due to a point mutation in FV (Arg506Gln); which was later referred to as 
factor V Leiden (Bertina et al., 1994; Greengard et al., 1994; Voorberg et al., 1994). 
In 1993, mild to moderate hyperhomocysteinemia was recognized as a risk factor for venous 
thrombosis (Bienvenu et al., 1993).   
In 1996, a single nucleotide polymorphism was indicated in the 3'-untranslated region of the 
prothrombin gene (G20210A) and linked to familial venous thromboembolism (Poort et al., 
1996). 
After that, many experiments proved a positive relationship between elevated levels of FVIII 
in plasma and venous thrombosis, but no genetic factors could be identified (Kamphuisen et 
al., 2000a; Koster et al., 1995; Schambeck et al., 2001).  
1.1.1.2.1. Major hereditary defects: 
Among the main genetic defects that correlate with thrombosis are: a point mutation in F5 
gene that cause resistance to the APC; known as FV Leiden, another one is a point mutation 
in the 3' untranslated region of F2 gene; that causes hyperprothombinemia, both of which 
are considered to be the most frequent among the genetic causes of thrombophilia (Ta-
ble 1.2).  Hyperhomocysteinemia and GP β3 pro33 are, also, of the mentioned risk factors 
that are correlated with high tendency towards developing thrombosis (Iolascon et al., 2001). 
 
Table 1.2: Genetic defects in inherited thrombophilia.  
Genetic defect Prevalence% Mutations* 
Dysfibrinogenemia 1.0 > 11 
Antithrombin deficiency 4.3 > 79 
Protein C deficiency 5.7 > 160 
Protein S deficiency 5.7 > 69 
APC resistance 45 1 
Increased prothrombin 18 1 
Unknown 30 ? 
(Bertina, 1997) 
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1.1.1.2.1.1. Prothrombin gene mutation (G20210A): 
The activated form of prothrombin, thrombin (factor IIa, FIIa) is the central protease in the 
coagulation cascade and one of the most widely studied enzymes.  It was described in 1892 
by Alexander Schmidt, but the first identification of thrombin was set in 1845 by Buchanan 
(Siller-Matula et al., 2011). 
The gene coding for prothrombin (FII) is located on chromosome 11p11 (Chromosome 11, 
NC_000011.9: 46,740,743-46,761,056), and is termed as (F2) gene.  It spans (20,314 bp) 
consisting of 14 exons separated by 13 introns (Degen and Davie, 1987; Royle et al., 1987) 
(Figure 1.1). 
 
 
Prothrombin is a glycoprotein synthesized by the liver parenchyma cells as a proenzyme 
with a molecular weight approximately (72 KDa) consisting of (579) amino acid residues.  
Activation of prothrombin to thrombin takes place by sequential cleavages at two argenin 
residues (Arg320 and Arg271) by the prothrombinase complex (FXa, FVa and Ca++( on a 
phospholipid surface.  FIIa is a heterodimer consisting of two polypeptide chains with a 
molecular weight of approximately 37 KDa (Degen and Davie, 1987; Matafonov et al., 
2011). 
Thrombin is a vitamin K dependent serine protease enzyme, which exhibits a trypsin-like 
specificity and cuts at specific Arg residues of the substrate.  Thrombin acts on twelve known 
Figure 1.1: F2 gene location.   
The F2 gene is located on the short arm (p) of chromosome 11 at position 11, as indicated 
by the arrow (Genetics Home Reference, 2008). 
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substrates with the assistance of five cofactors.  Upon activation of thrombin in a reasonable 
amount many vital activities are carried out, termed as (Thrombin burst); which involve the 
action of thrombin on various lines and systems including coagulation and complement sys-
tems, as well as other roles in various vital processes throughout the body tissues (Bode, 
2006).   
Thrombin converts fibrinogen (FI) into active fibrin monomers (FIa).  Then, it stabilizes the 
fibrin monomers by activating the transglutaminase (FXIII) that cross links the fibrin mon-
omers and produces a clot mesh of fibrin polymers (Di Cera, 2003).  Thrombin, also, is a 
potent activator of the nearby platelets via protease- activated receptors 1, 3 and 4 (PARs1,3 
and 4) (Kahn et al., 1998); a single thrombin-activated platelet exposes more than 12,000 
copies of GP(αIIbβ3) receptors that can concentrate fibrinogen for efficient fibrin formation 
(Peerschke et al., 1980).  Subsequently, many coagulation factors (i.e. FV, FVII, FVIII and 
XI) bind to the activated platelet membrane in order for subsequent coagulation steps to take 
place.  Activation of these factors feeds positively on the formation of the prothrombinase 
complex, which intensifies the thrombin burst action (Lancellotti and De Cristofaro, 2009).   
Thrombin, also, activates Thrombin Activatable Fibrinolysis Inhibitor (TAFI), which inhib-
its plasmin-mediated fibrinolysis, and thus, facilitates plasminogen binding, from partially 
degraded fibrin (Lancellotti and De Cristofaro, 2009; Pihusch et al., 2001). 
In addition to its procoagulant activity, thrombin has an anticoagulant function.  Upon bind-
ing of thrombin to its receptor on the endothelium, thrombomodulin (TM), it exhibits its 
anticoagulant role in the coagulation process (Esmon, 1995).  Here, the ability of thrombin 
to cleave fibrinogen and PAR1is suppressed.  In contrast, it enhances its affinity towards the 
zymogen; protein C by more than a thousand fold (Di Cera, 2003).  APC cleaves and inac-
tivates FVa and VIIIa; which are two essential cofactors for the action of coagulation factors 
Xa and IXa, which are required for thrombin generation, thereby, feeds negatively on the 
progression of the coagulation cascade, and so, on its production (Di Cera, 2003). 
Thrombin also activates tissue components represented in the placenta and plays a role in 
cell adhesion, smooth muscle proliferation, and vasculogenesis.  Thrombin also has growth 
factor and cytokine-like activities that may play a role in atherosclerosis, wound healing, and 
inflammation (Siller-Matula et al., 2011).  Thrombin plays a role in arterial and venous 
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thrombosis as wells as in the pathogenesis of multiple conditions, e.g. sepsis and dissemi-
nated intravascular coagulation (DIC), cancer, inflammatory brain diseases, wound healing 
and atherosclerosis (Siller-Matula et al., 2011).   
Finally, thrombin is irreversibly inhibited at its active site by the serine proteases  antithrom-
bin (AT) and protease nexin I which are assisted by heparin and the thrombin-specific hep-
arin cofactor II, that regulates the growth factor and cytokine-like activities of thrombin 
(Davie and Kulman, 2006; Muszbek et al., 2010; Siller-Matula et al., 2011). 
1.1.1.2.1.1.1. Prothrombin deficiency: 
Hypoprothrombinemia, or congenital prothrombin deficiency, is a rare autosomal recessive 
disorder characterized by low thrombin antigenic levels and activity below 10% of the nor-
mal patient which lead to severe bleeding manifestations (Lancellotti and De Cristofaro, 
2009).  Dysprothrombinemia, which is characterized by normal antigen levels but a dysfunc-
tional prothrombin molecule, shows a more variable level in bleeding tendency, and there is 
often a good correlation between the levels of prothrombin activity and clinical severity.  It 
has been stated that 32 molecular defects in prothrombin were identified (Akhavan et al., 
2002; Lancellotti and De Cristofaro, 2009).  Complete prothrombin deficiency, or aprothom-
binemia, is believed to be incompatible with life (Meeks and Abshire, 2008). 
1.1.1.2.1.1.2. Hyperprothrombinemia: 
A common genetic variation in the 3' untranslated region of the prothrombin gene 
(G20210A) was noticed to correlate with elevated plasma prothrombin levels and an in-
creased risk of venous thrombosis (Poort et al., 1996) (Figure 1.2).  This single base substi-
tution was found in 18% of thrombophilic families, 6% of unselected consecutive patients 
with deep-vein thrombosis, and 2% of healthy controls (Rosendaal et al., 1997).  Moreover, 
it was found that this mutation was associated with a 4-fold increased risk of myocardial 
infarction in women (Rosendaal et al., 1997), while among men the risk was increased up to 
1.5 folds (Doggen et al., 1998). 
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Figure 1.2: The prothrombin gene (G20210A) mutation.   
The single point G to A mutation at position 20210 affects the 3' untranslated region of the pro-
thrombin gene (F2).  Thus, the protein-coding sequence of the prothrombin gene is not affected by 
this mutation. (Dahlback, 2008a). 
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1.1.1.2.1.2. Activated Protein C Resistance (APCR): 
Most inherited risk factors for venous thrombosis are found in the protein C system.  Any 
inherited or acquired abnormality that interferes with the expression of Activated Protein C 
APC activity is termed as Activated Protein C Resistance (APCR) (i.e. auto-antibodies and 
serine protease inhibitors) (Oosting et al., 1993; Zivelin et al., 1999).  However, the most 
common cause of hereditary thrombophilia is a point mutation in the F5 gene, which is 
known as FV Leiden (Bertina et al., 1994; Svensson and Dahlback, 1994). 
1.1.1.2.1.2.1. Factor V: 
Factor V (also called proaccelerin or the labile factor) is encode by the (F5) gene which is 
located on chromosome (1q23), as shown in Figure (1.3), and spans (75,774 bp) consisting 
of 25 exons (Duga et al., 2004; Galanello et al., 2001).  FV is produced as a pre-procofactor 
protein with (2224 aa) long and weighs (330 kDa) (Tracy et al., 1982). 
 
About 80% of the blood FV is produced and secreted by the hepatocytes and circulates in 
the plasma at a concentration of about (7 µg/mL) (Tracy et al., 1982).  Most of the remaining 
20% is produced by the megakaryocytes and is stored, as a partially proteolyzed protein, in 
the alpha (α) granules of the platelets (about 4600 – 14,000 molecules per platelet) (Gewirtz 
et al., 1986).  Some of this stored FV was noticed to be absorbed from the plasma via endo-
Figure 1.3: F5 gene location.  
The F5 gene location is located on the long (q) arm of chromosome 1 at position 23, as indicated 
by the arrow (Genetics Home Reference, 2013a). 
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cytosis (Camire et al., 1998).  This platelet-derived FV is that responsible for thrombin gen-
eration at the primary plug site upon platelet activation at the injury site (Mann and Kalafatis, 
2003; Nicolaes and Dahlback, 2002). 
Factor V has almost no procoagulant activity until it is proteolytically activated by thrombin 
or by activated factor X (FXa).  FV activation involves proteolysis at three arginine residues 
(Arg709, Arg1018, and Arg1545) (Guinto and Esmon, 1982; Nicolaes and Dahlback, 2002).  
Upon activation of FV, activation of thrombin increases by 300,000 folds relative to the rate 
of the reaction catalyzed by factor Xa acting alone (Mann and Kalafatis, 2003; Nicolaes and 
Dahlback, 2002). 
FV has a dual action depending on the nearby microenvironment; in the presence of FIIa or 
FXa the precursor of FV is proteolyzed in a way directing the molecule towards its procoag-
ulant fate (FVa) where it is involved in the formation of the prothrombinase complex; which 
activates prothrombin to thrombin.  Alternatively, cleavage by APC may recruit FV towards 
its anticoagulant fate (FVac) where it acts as a cofactor for APC, which inactivates FVIII 
(Shen and Dahlback, 1994; Thorelli et al., 1999).   
Down regulation of the procoagulant activity of FVa is achieved, mainly, by APC; which 
involves proteolysis at three arginine residues (Arg506, Arg306, and Arg679).  Kinetically, 
the Arg506 residue is the highest, then Arg306 and, finally, Arg679 residue is the slowest 
(Dahlback, 1999; Nicolaes et al., 1995).  Moreover, the Arg306 site seems to be the most 
important for FV inactivation in vivo; where it is potentiated 20 folds in the presence of 
protein S.  Whereas Arg506 seems to be more important in the regulation of free FVa 
(Dahlback, 1999). 
The first cleavage, at Arg506, reduces both FVa cofactor activity (by 25 – 40%) and its 
affinity for FXa, resulting in partial inactivation of FVa.  The subsequent cleavage at Arg306 
leads to the complete inhibition of FVa, while Arg679 cleavage seems to be with the least 
importance (Dahlback, 1999; Nicolaes et al., 1995). 
Another mechanism for FVa inactivation involves thrombin-mediated cleavage at Arg643 
site, in the presence of endothelial cells, which results in the reduction of the affinity between 
the heavy and the light chains of the molecule (Mann and Kalafatis, 2003). 
 19 
 
Down regulation of the anticoagulant activity of FVac is achieved, mainly by thrombin pro-
teolysis at three arginine residues (Arg709, Arg1018, and Arg1545).  Moreover, it was found 
that FVac could be cleaved by thrombin at both Args (709 and 1018) and still work fully as 
a cofactor to APC, whereas cleavage at (Arg 1545) completely eliminates the anticoagulant 
activity of FV (Thorelli, 1999). 
As FV has a dual role; as procoagulant and anti-coagulant agent, defects in F5 gene result in 
either an autosomal dominant form of thrombophilia (i.e. APCR) or in hemorrhagic compli-
cations with an autosomal recessive mode of inheritance (Asselta et al., 2006). 
1.1.1.2.1.2.1.1. FV mutations:  
Twenty-four mutations were identified to result in FV deficiency; a very rare bleeding dis-
order (1:1,000,000).  Deficiency in FV was subdivided into type I; very low or un- measur-
able antigen level, or type II; normal or mildly reduced antigen levels associated with re-
duced coagulant activity.  Severe type I is termed as parahemophilia or Owren parahemo-
philia, which is inherited in an autosomal recessive fashion, and the mutation was identified 
in 1998.  Sixteen mutations of the twenty-four give rise to null alleles; either due to nonsense 
or to frame-shift mutations, which are thought to result in mRNA instability.  The other three 
mutations (Cys472Gly, Val1813Met, and Arg2074Cys) were found to impair FV secretion 
(Duga et al., 2003; Montefusco et al., 2003; Owren, 1947; van Wijk et al., 2001).  
1.1.1.2.1.2.1.2. Factor V Leiden: 
In 1994, a point mutation in FV (G1691A) was identified (Bertina et al., 1994).  This form 
was termed FV Leiden, and was described as the most common genetic cause for thrombosis 
(Bertina et al., 1994; Svensson and Dahlback, 1994).  The mutation (Arg506Gln) causes 
resistance to inactivation of FV by APC as it affects the 506 site, which is the first and the 
favorable site for proteolysis by APC, and so, interferes with the FVac activity and inactiva-
tion of FVIIIa (Bertina et al., 1994). 
Thromboembolic episodes associated with FV Leiden are almost exclusively venous in na-
ture.  Although rare case reports linked FV Leiden to arterial thrombosis.  FV Leiden, has 
been found in 30 to 60% of cases of familial thrombophilia in patients of various ethnic 
origins and in 3 to 7% of healthy people in two white populations.  A large number of studies 
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has estimated the increase in risk for venous thrombosis due to FV Leiden to be 7-folds for 
heterozygous carriers and 80-folds for homozygous carriers of the mutation (Rosendaal et 
al., 1995; Simioni et al., 2005).  
Besides FV Leiden, two additional FV allelic variants have been reported in patients with 
APC resistance: FV Cambridge and FV Hong Kong, where they affect the second and the 
most important site for FV inactivation and responsible for the complete loss of FVa pro-
coagulant activity in vivo (i.e. Arg306), but the amino acid substitution in both is different, 
which is (Arg306Thr) and (Arg306Gly) for FV Cambridge and FV Hong Kong, respectively 
(Norstrom et al., 2002).  FV Cambridge was identified in individuals with unexplained APC 
resistance and seems to be an extremely rare mutation.  In contrast, FV Hong Kong is com-
mon in certain Chinese populations but does not appear to be a risk factor for thrombosis 
(Nicolaes and Dahlback, 2002).  On the other hand, some articles didn’t find any association 
between those two variants and any increase in the risk for thrombosis at the population level 
(Duga et al., 2004).  
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1.1.1.2.1.3. Methylenetetrahydrofolate reductase mutation (C677T): 
5,10-Methylenetetrahydrofolate reductase (MTHFR) catalyzes a rate-limiting step in the me-
tabolism of folate within the methionine - homocysteine pathway (Figure 1.4); it catalyzes 
the conversion of 5,10-methylenetetrahydrofolate to 5-methyltetrahydrofolate, a co-sub-
strate for homocysteine remethylation to methionine (Fodinger et al., 2000).   
 
The gene encoding the MTHFR is located on chromosome 1p36.3 (Chromosome: 1; 
NC_000001.10, 11845787-11866160, complement), and is termed as (MTHFR) gene (Fig-
ure 1.5).  It spans (20,374 bp) consisting of 11 exons (Gaughan et al., 2000; Goyette et al., 
1998; Goyette et al., 1994). 
Figure 1.4: Homocysteine and folate cycle. 
Methylenetetrahydrofolate reductase catalyzes the conversion of 5,10-methylenetetrahydrofolate to 
5-methyltetrahydrofolate, a cosubstrate for homocysteine  remethylation to methionine.  5-Methyl-
tetrahydrofolate is used to convert homocysteine (a potentially toxic amino acid) to methionine by 
the enzyme methionine synthase.  Absence or low activity of the MTHFR leads to accumulation of 
homocysteine in cells which leads to homocysteinemia and homocysteinurea (Hoffbrand, 2011). 
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The mammalian MTHFR has at least two isoforms (70 kDa and 77 kDa), and is composed 
of an N-terminal catalytic domain and a C-terminal regulatory domain (Tran et al., 2002).  
The enzyme activity could be regulated by negative feedback inhibition of dihydro-
folate (DHF) and S-adenosylmethionine (SAM) (Jencks and Mathews, 1987; Matthews and 
Daubner, 1982; Miller et al., 1994).  In addition, phosphorylation of MTHFR can decrease 
its activity by 20%, and this allows it to be inhibited more easily by SAM (Yamada et al., 
2005).  Twenty-four polymorphisms of the MTHFR were described until the 2000; two of 
the most investigated are C677T (rs1801133) and A1298C (rs1801131) (Sibani et al., 2000; 
Tran et al., 2002). 
1.1.1.2.1.3.1. Hyperhomocysteinemia and MTHFR (C677T): 
Hyperhomocysteinemia is a known risk factor for cardiovascular and cerebrovascular dis-
eases (Cattaneo, 1999), atherosclerosis and recurrent arterial and venous thrombosis, usually 
in the third or fourth decade of life (Rees and Rodgers, 1993; Welch and Loscalzo, 1998), 
where plasma homocysteine concentration exceeds 15 µM (Guo et al., 2009). 
In the 1995 a point mutation (C677T) was identified which results in the substitution of 
alanine by valine (Ala222Val) and production of a thermolabile form of MTHFR (Frosst et 
al., 1995), and an enzyme with 30 – 50% of the activity of the wild-type enzyme in vitro and 
is associated with hyperhomocysteinemia (Goyette and Rozen, 2000; Sibani et al., 2000).  
The wild type form was designated as (667CC), while the homozygous form was designated 
as (667TT), and the heterozygous (667CT) (Friso et al., 2002).  Hyperhomocysteinemia  due 
Figure 1.5: The MTHFR gene location.  
The MTHFR gene is located on the short (p) arm of chromosome 1 at position 36.3, as indicated 
by the arrow (Genetics Home Reference, 2011). 
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to the (C677T) mutation has been suggested as a risk factor for venous thrombosis, heart 
diseases, strokes, hypertension, preeclampsia, glaucoma (eye disorder), cleft lip and palate,  
Acute Lymphocytic Leukemia (ALL) and several other diseases by interfering with the 
cross-linking between the collagen fibers (Boers et al., 1985; Botto and Yang, 2000; Clarke 
et al., 1991; Dietrich-Muszalska et al., 2012; Fodinger et al., 2000; McLean et al., 2004a; 
McLean et al., 2004b; Morris, 2003; Robien and Ulrich, 2003; Schmidt et al., 2011; Stampfer 
et al., 1992; Ulrich et al., 2003). 
In 2002, two sisters were described to be homozygous for the (C677T) mutation and heter-
ozygous for three other mutations.   The problem was noticed when one of the sisters (27 
years) developed pulmonary embolism due to venous thrombosis 8 months after taking oral 
contraceptives.  On the other hand, her sister (26 years) had intellectual retardation and a 
slow gait.  At the age of 5 years, she developed seizures, walking difficulties, and mental 
retardation.  The father developed myocardial infarction at the age of 48 years.  The mother 
had never expressed venous or arterial thrombosis but had been treated with folic acid be-
cause of mild hyperhomocysteinemia (Tonetti et al., 2002).  In the same year (2002), a case 
(42 years) man was reported of renal artery thrombosis, who was homozygous for the 
(C677T) mutation and had a low folate level (Queffeulou et al., 2002).  Another group found 
that both hyperhomocysteinemia due to the (C677T) mutation and factor V Leiden are risk 
factors for recurrent venous thrombosis  (Keijzer et al., 2002).  In a comprehensive meta-
analysis involving 32 genes involving approximately (18,000) patients and (58,000) con-
trols, a statistically significant association was found between ischemic stroke and the 
(C677T) substitution (Casas et al., 2004). 
In a study, more than 7,000 newborns from 16 areas in Europe, Asia, the Americas, the 
Middle East, and Australia were examined for geographic and ethnic distribution of the 
(C667T) polymorphism (Wilcken et al., 2003).  Results showed that the (667TT) genotype 
was common in northern China (20%), southern Italy (26%), and Mexico (32%).  There was 
also some evidence for geographic gradients in Europe (i.e. increases from north to south) 
and China (i.e. decrease from north to south).  The (667TT) genotype frequency was low 
among newborns of African ancestry, intermediate among newborns of European origin, and 
high among newborns of American Hispanic ancestry.  The findings suggested the existence 
of selective pressures leading to this marked variation (Wilcken et al., 2003). 
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Hyperhomocysteinemia also occurs in a rare hereditary disease homocystinuria; due 
to cystathionine beta synthase deficiency (CBS deficiency), an inherited autosomal recessive 
disorder, and is associated with multi-systemic disorders of the connective tissue, mus-
cles, neuropathy, and cardiovascular system (Reish et al., 1995).   
However, acquired hyperhomocysteinemia in the absence of any mutation or polymorphism 
may be caused by vitamin deficiencies (e.g.  folic acid (B9), pyridoxine (B6) or cobalamin 
(B12)), pernicious anemia, renal failure, diabetes mellitus, hypothyroidism, some carcino-
mas, inflammatory bowel disease, and methotrexate, theophylline, or phenytoin therapy 
(Guba et al., 1999; Welch and Loscalzo, 1998). 
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1.1.1.2.1.4. The GP (β3) (T1565C) polymorphism 
Platelet adhesion, spreading and aggregation are mediated by a specific receptor on the plate-
let surface (glycoprotein αIIbβ3) (Bennett, 1990; 2008; Pastinen et al., 1998; Plow and 
Byzova, 1999). 
Glycoprotein (αIIbβ3), also known as GP (IIb/IIIa), is a heterodimer transmembrane (integ-
rin) protein composed of two subunits (α & β) (Fujimura and Phillips, 1983).  Each subunit 
is the product of a separate gene; the (α) subunit or the (αIIb) is encoded by the Integrin αIIb 
(ITGA2B) gene; which locates on chromosome 17q21.32 (Chromosome: 17; NC_000017.10 
(42,449,549 - 42,466,872), and the (β) subunit or the (β3) is encoded by the Integrin β3 
(ITGB3) gene; which is located on chromosome 17q21.32 (Chromosome: 17; 
NC_000017.10 (45,331,208 - 45,390,077) ( Figure 1.6).  
 
 
 
 
 
 
Both subunits are synthesized as single glycosylated polypeptide chains; the (ITGB3) gene 
gives the (β3) integrin, which is known, also, as (CD61) polypeptide, while the 
(ITGA2B) gene gives the (αIIb) integrin, which is known, also, as (CD41) polypeptide.  Each 
integrin consists of a large extracellular region, transmembrane region, and a short cytoplas-
mic tail (Xiao et al., 2004; Xie et al., 2004; Zimrin et al., 1990), as illustrated in Figure (1.7). 
GP (αIIbβ3) is the major integral plasma membrane protein in platelets; it represents (3%) 
of the total platelet proteins and (17%) of the platelet membrane protein mass (Phillips et al., 
 Figure 1.6: The GP β3 gene location.  
The GP β3 gene is located on the long (q) arm of chromosome 17 at position 21.32, as indicated by 
the arrow (Genetics Home Reference, 2013b). 
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1988).  Each platelet expresses about (80,000 - 100,000) copies of GP (αIIbβ3) (Niiya et al., 
1987; Wagner et al., 1996).  The platelet α-granule membranes also contain a GP (αIIbβ3) 
pool, which could be expressed upon platelet stimulation (Berman et al., 1986; Wencel-
Drake et al., 1986). 
This  protein complex has the capacity to undergo activation (i.e. transformation from low-
affinity resting state to a high-affinity active state) upon stimulation by adenosine diphos-
phate (ADP), epinephrine, collagen, or thrombin, which allows it to act as a fibrin and von 
Willebrand factor receptor (Calvete, 1999; Prandini et al., 1988; Vickers, 1999).  Moreover, 
it can recognize and bind other ligands (e.g. vitronectin, fibronectin, and thrombospondin) 
which mediate platelet adhesion to the subendothelial matrix and regulate platelet aggrega-
tion (Hynes, 1992; Plow et al., 2000). 
 
 
 
 
 
 
 
 
 
In addition to their physiological role on platelets, surface proteins can express many alloan-
tigenic determinants (Kunicki and Newman, 1986).  Both (α) & (β) subunits of the GP 
(αIIbβ3) are known to bear a number of clinically important epitopes that are responsible for 
triggering alloimmune response and platelet destruction syndromes; particularly, postrans-
fusion purpura (PTP) and neonatal alloimmune thrombocytopenic purpura (NATP) (Kunicki 
and Newman, 1986; Newman et al., 1989).  There are at least seven alleles of the GP (β3) 
Figure 1.7: Schematic model of Glycoprotein (αIIbβ3) structure.  
(Downes and McCrae, 2005). 
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(Newman, 1994), but the most common and clinically important alloantigens are in the Plate-
let-specific Alloantigen (Pl(A)), which is a part of the external cellular domain of the (β) 
subunit of the GP (αIIbβ3) (i.e. β3).  There are two serologically defined antigens of the 
Pl(A): Pl(A1) and Pl(A2) (Kunicki and Newman, 1986; Newman et al., 1989).  These plate-
let alloantigens, Pl(A1) and Pl(A2), were shown to associate with (Leu33) and (Pro33) amino 
acid polymorphism, respectively (Newman et al., 1989).  This polymorphism results from a 
(C1565T) substitution  in the exon 2 of the ITGB3 gene (Newman et al., 1989). 
The gene frequency for Pl(A1) in Caucasians is about (85%) and for Pl(A2) it is about (2%) 
(Newman et al., 1989)  and among the Amerindians it is (4.2%); which is lower than that 
obtained for blacks and whites which were (14.8% and 10%) respectively (Covas et al., 
1997).  The gene frequency of the (PIA2) allele in Koreans is very low (0.5%).  But, no 
significant differences were found in the gene frequencies of the human platelet antigens in 
European whites (Kim et al., 1995).  Since most of the population carries the Pl(A1) antigen, 
Pl(A2) homozygotes are at risk of producing anti- Pl(A1) antibodies against paternally in-
herited Pl(A1) antigens presented on fetal platelets, and are most likely to develop (NATP), 
or (PTP) after blood transfusion (Newman et al., 1989).   
Given its importance in adhesion, spreading and aggregation of the platelets, studying of GP 
(αIIbβ3) polymorphisms and mutations occupied a large sector of studying and examining 
their role in bleeding and thrombotic events (2008).  Most GP (αIIbβ3) mutations lead to an 
inherited autosomal recessive bleeding disorder, Glanzmann thrombasthenia; which is a dis-
ease characterized by production of defective or low levels of the GP (αIIbβ3)  (Kannan and 
Saxena, 2009).  The presence of the Pl(A2) allele was shown to associate with increased 
platelet activation and aggregability (Feng et al., 1999; Michelson et al., 2000), defective 
platelet response to arachidonic acid and thromboxane (A2) (Andrioli et al., 2000) and more 
tendency to bind fibrinogen (Vijayan et al., 2000).  It was, also, associated with enhanced 
thrombin formation and impaired antithrombotic action of aspirin, which might favor coro-
nary thrombosis in the Pl(A2) carriers (Undas et al., 2001).  Pl(A2) homozygosity is associ-
ated with a three to four-fold risk of ischemic and thrombotic cardiovascular disease and MI 
in young men (Bojesen et al., 2003a; Byzova and Plow, 2000; Galasso et al., 2010), increased 
risk for cancers (Bojesen et al., 2003b) and a two-fold risk of hip fracture, mainly confined 
to postmenopausal women (Tofteng et al., 2007).  Furthermore, Pl(A2) positive individuals 
show significantly shorter bleeding times than Pl(A1) individuals (Bray, 2000).  The PlA2 
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polymorphism also enhances cell spreading, actin cytoskeleton rearrangement and clot re-
traction (Bray, 2000), and a lowers the threshold for GP (αIIbβ3) activation and α-granules 
release of the protein (Michelson et al., 2000).  Moreover, it was shown that having Pl(A2) 
antigen might have implications for antiplatelet therapy of patients with MI (Grove et al., 
2004). 
However, the clinical implications of these in vitro studies and the role of GP (αIIbβ3) pol-
ymorphisms in genetic susceptibility to thrombotic diseases remain controversial (Bray, 
2000); some data suggest that the Pl(A2) allele may be a weak risk factor for myocardial 
infarction in young men (Clemetson, 2008).  Moreover, many other research groups didn’t 
find any contribution of the Pl(A1)/Pl(A2) polymorphism in developing of coronary athero-
sclerosis or the genetic susceptibility to premature myocardial infarction (Lagercrantz et al., 
2003) or any association with DVT (Renner et al., 2001). 
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1.2 β-Thalassemia 
Beta Thalassemia (βT) is a congenital extra-vascular hemolytic anemia that is caused by a 
defect in the β- globin gene, which results in a reduction (β+), or absence (β0), of the produc-
tion the β- globin chains, an integral component of the heterodimer (α2β2) adult hemoglobin 
(Hb A) molecule.  This disease affects multiple organs and systems, and is associated with 
considerable morbidity and mortality around the world (Cohen et al., 2004).  Thalassemia is 
among the most common genetic disorders worldwide; about 4.83% of the world’s popula-
tion carry globin variants, including 1.67% of the population who are heterozygous for α-
thalassemia and β-thalassemia (Skordis et al., 1998).  It was estimated that the incidence of 
symptomatic individuals is about 1 in 100,000 throughout the world and 1 in 10,000 people 
in the European Union (Vichinsky, 2005).  The prevalence of β-thalassemia trait among the 
Palestinian population in the West Bank was estimated to be 3.5% (Darwish et al., 2005). 
One of the main problems in β-thalassemia is the imbalance in the production of both globin 
chains (α and β) which constitute the adult hemoglobin.  In β- thalassemia, excess α- globin 
chains precipitate in the RBCs and mainly on their plasma membranes which results in the 
reduction of the life span of the cells, and eventually, evolution of hemolytic anemia (Taher 
et al., 2009; Weatherall and Clegg, 2001). 
Classification of βT depends on several factors; such as the clinical picture of the disease, 
the severity of the anemia and blood transfusion requirement.  Depending on these factors 
and others (i.e. genetic) thalassemia could be classified into β-thalassemia minor, thalasse-
mia intermedia (TI) and β-thalassemia major (β-TM) (Musallam et al., 2012; Olivieri, 1999; 
Rund and Rachmilewitz, 2005). 
1.2.1. β-Thalassemia major (β-TM): 
This type was formerly named “Cooley's anemia” after Dr. Thomas Benton Cooley, who 
was the first to describe this syndrome in 1925 in five young children with severe anemia, 
splenomegaly, and peculiar bone abnormalities (Cooley and Lee, 1925).  It is the most severe 
case; where the patient expresses the homozygous state (β0/β0) having almost complete loss 
of the β- chain production, and expressing fetal hemoglobin (Hb F) as the main hemoglobin 
in his RBCs (Error! Reference source not found.).  Patients present with severe microcytic 
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hypochromic anemia between 6 and 24 months of age, fail to thrive and become progres-
sively pale.  They suffer from severe bone deformities and progressive abdominal enlarge-
ment caused by splenohepaotmegaly.  Management is achieved by periodic lifelong blood 
transfusion, with iron chelation and splenectomy in parallel, which, if taken regularly, makes 
the patient to progress to live beyond 40 years (Galanello and Origa, 2010).  Currently, the 
available way of possibly curing this disease is bone marrow transplantation (Weatherall, 
2004).  Gene therapy, on the other hand, is a promising strategy for curing thalassemia 
(Lisowski and Sadelain, 2008; Quek and Thein, 2007; Xie et al., 2007). 
1.2.2. β-Thalassemia minor: 
Here, patients have a heterozygous state (β0/β or β+/β) and show minor loss of β- chain pro-
duction, and slight microcytic (MCV 50 – 70 fL) hypochromic (Hb 9 – 11 g/dL) anemia.  
The red cell count is usually normal or elevated, with an increase in hemoglobin A2 (Hb 
A2) fraction (3.5 – 7%) and dominancy of the adult hemoglobin (Hb A) fraction, and the 
fetal Hb sustains normal with rare elevation above 5%.  Patients sustain in a clinically asymp-
tomatic status until they are exposed to a stressful situation or disease where sometimes sup-
porter medication is needed (Weatherall, 2006). 
1.2.3. Thalassemia intermedia (TI): 
Naming of this type of thalassemia “Intermedia” was put in 1955 by Dr. Sturgeon, which 
came from the clinical situation of the patients who express symptoms that are too severe to 
be termed minor and too mild to be termed major with moderate to severe anemia (Musallam 
et al., 2012; Sturgeon et al., 1955).  Most TI patients are homozygotes or compound hetero-
zygotes (β+/β+ or β+/β0) for one or more beta-thalassemia mutations (Galanello and Cao, 
1998).  Finding a relationship between genotype and phenotype in TI is so complicated, and 
many modifiers can affect the outcome of a certain mutation (Galanello and Cao, 1998).   
Thalassemia intermedia is not a definite type that is produced due to a defined genetic defect; 
rather, it is a collection of factors combined together to produce this phenotype (Taher et al., 
2009).  For example, coexistence of α- thalassemia trait decreases the severity of the disease 
due to the decrease in the imbalance between α and β chains (Weatherall, 1995).  Another 
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factor, is the coinheritance of a mutation in the γ gene (i.e. γG XmnI); which is a polymor-
phism that results in an over production of the γ- chain and helps to neutralize large propor-
tion of unbound α- chains which produces higher levels of Hb F (Camaschella et al., 1995).  
On the other hand, the TI phenotype may result from increased production of α-globin chains 
by a triplicated or quadruplicated alpha genotypes associated with the existence β-thalasse-
mia heterozygosity (Camaschella et al., 1997).  Other criteria are followed to differentiate 
between β-TM and TI as shown in Table (1.3) (Taher et al., 2009). 
Table 1.3: Thalassemia Intermedia vs. β-Thalassemia Major. 
Parameter β-TM* more likely TI* more likely 
Clinical 
Presentation year < 2 > 2 
Liver/Spleen enlargement Severe Moderate to severe 
Hematological 
Hb level (g/dL)* 6 – 7 7 – 10 
Hb F > 50 10-50 (may be up to 100%) 
Hb A2 < 3.5 > 3.5 
Genetic 
Parents 
Both carriers of high 
Hb A2 β-thalassemia 
One or both atypical carrier: 
- High Hb F  β-thalassemia 
- Borderline Hb A2 
Molecular 
Type of mutation Severe Mild/Silent 
Co-inheritance of α-thalassemia No Yes 
Co-inheritance of extra α-alleles  Yes No 
HPFH* No Yes 
δβ-thalassemia No Yes 
γG XmnI polymorphism No Yes 
β-TM: β-Thalassemia Major.  TI: β-Thalassemia Intermedia.  Hb: hemoglobin.  HPFH: Hereditary 
Persistence of Fetal Hemoglobin.  
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1.2.3.1. Pathophysiology in TI: 
A good and acceptable phenotype scoring system was proposed in 2003 tried to sub-classify 
TI patients into three separate groups: mild, moderate and severe.  The severity of TI was 
graded according to a number of clinical features; such as age at presentation, severity of 
anemia, extent of growth retardation, bone marrow hyperplasia, blood transfusion require-
ments and need for splenectomy (Phadke and Agarwal, 2003). 
The disease manifests itself in many aspects; in one hand, hemolysis and ineffective eryth-
ropoiesis, due to the precipitation of the unstable α- chains within erythroid precursors in the 
bone marrow causing membrane damage and cell death, are the cause of the anemia 
(Pootrakul et al., 2000).  On the other hand the bone marrow mass expands due to Hypertro-
phy of erythroid lineage in medullary and extramedullary sites in order to compensate the 
loss in the RBC compartment in the peripheral blood.  Consequently, characteristic bone 
deformities and shape changes result in thalassemic patients (Olivieri, 1999).  Add to this, 
the iron overload complications which develop primarily due to increased intestinal iron 
absorption, in contrast to patients with β-TM, in whom iron loading occurs mainly as a result 
of the blood transfusion therapy (Origa et al., 2007).  Iron deposits in various body tissues 
causing severe toxicity for many organs; including endocrine disturbances (e.g. diabetes 
mellitus and hypogonadism) typically by the fourth decade of life (Taher et al., 2009).  Fur-
thermore, high incidence of pigment gallstones, bone and joint disease and leg ulcer are 
observed in these patients (Taher et al., 2009). 
Consequently, several complications have been identified in patients with TI, and some of 
these complications have been noticed to be unique to TI over β-TM (Table 1.4), especially 
in splenectomized transfusion naive patients (Taher et al., 2006a).  Cholelithiasis gallstones 
are much more common in TI than in β-TM patients because of ineffective erythropoiesis 
and peripheral hemolysis (Galanello et al., 2001).  Moreover, Gilbert’s syndrome has been 
reported to increase gallstone formation in patients with thalassaemia (Borgna-Pignatti et al., 
2003; Galanello et al., 2001).  Leg ulcers are more common in older patients with TI than 
younger patients (Taher et al., 2006a).  It was noticed that ulcers develop in some patients 
who are maintained at relatively low Hb levels and have the same amount of Hb F as others 
whom ulcers do not develop in, due to an unclear reason, and these patients suffer from 
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fragile, very painful and difficult to cure skin lesions at their extremities (Musallam et al., 
2012).   
Pulmonary hypertension is considered as a part of the clinical complications for adult β-
thalassemia patients, with a frequency ranging from 10% to 74% with higher rate in TI pa-
tients (Aessopos and Farmakis, 2005). 
Extra-medullary hematopoiesis is a compensatory mechanism that attempts to overcome the 
chronic anemia of TI patients by forming erythropoietic tissue masses in the spleen, liver 
and lymph nodes.  However, this tissue can cause neurological problems such as spinal cord 
compression and paraplegia, and intra-thoracic masses (Castelli et al., 2004; Haidar et al., 
2010). 
Table 1.4) provides some clinical complication that were recorded in TI and β-TM patients, 
with a focus on some complications that were noticed to be unique to TI patients over β-TM 
patients (Taher et al., 2009).  
Table 1.4: Prevalence of complications in TI vs. β-TM. 
Complication  
(% of patients affected) 
TI* β-TM* 
Lebanon 
(n=37) 
Italy 
(n=63) 
Lebanon 
(n=40) 
Italy 
(n=60) 
Splenectomy 90 67 95 83 
Cholecystectomy 85 68 15 7 
Gallstones 55 63 10 23 
Extramedullary hemopoiesis 20 24 0 0 
Leg ulcers 20 33 0 0 
Thrombotic events 28 22 0 0 
Cardiopathy 3 5 10 25 
Pulmonary hypertension 50 17 10 11 
Abnormal liver enzymes 20 22 55 68 
Hepatitis C virus infection 7 33 7 98 
Hypogonadism 5 3 80 93 
Diabetes mellitus 3 2 12.5 10 
Hypothyroidism 3 2 15 11 
 β-TM: β-Thalassemia Major.  TI: Thalassemia Intermedia.    
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1.2.3.1.1. Thalassemia and hypercoagulability: 
Among the complications that were correlated with different hemolytic anemias (HA) in-
cluding thalassemias are thrombotic and hypercoagulability states (Eldor and Rachmilewitz, 
2002; Taher et al., 2008).  Deep venous thrombosis (DVT), pulmonary embolism, leg ulcers 
and recurrent arterial occlusion have been described in patients with β-TM and TI from many 
countries (Akar et al., 1998; Cappellini et al., 2000; Taher et al., 2006b).  Most cases devel-
oped thrombosis spontaneously with no known risk factors, although some cases developed 
venous thrombosis after splenectomy (Michaeli et al., 1992; Taher et al., 2006b).  Evidence 
of asymptomatic brain damage, including ischemic lesions, has been reported by magnetic 
resonance imaging (MRI) in patients with TI and it was noticed to be inversely correlated 
with Hb level and age (Manfre et al., 1999).  Defective platelet aggregation in response to 
adenosine di-phosphate (ADP), epinephrine and collagen was noticed in β-TM patients 
(Eldor, 1978; Hussain et al., 1979).  On the other hand, splenectomy increases the number 
of circulating platelets, which leads to chronic platelets activation and shortened platelets 
life span caused by enhanced platelets consumption in β-TM and TI patients (Eldor et al., 
1989).  Furthermore, increased circulating platelet aggregates was shown in 71% of splenec-
tomized compared to 35% of non-splenectomized patients with TI/hemoglobin E disease 
(Winichagoon et al., 1981).  The existence of chronic platelet activation in thalassemia pa-
tients was confirmed by flow-cytometric studies, which demonstrated the presence of an 
increased fraction of platelets carrying the activation markers CD62P (P selectin) and CD63 
(Del Principe et al., 1993; Ruf et al., 1997).  Moreover, elevated plasma platelet factor 3 
(PF3) was noticed in TI/Hb E patients, which increases platelet aggregation (Opartkiattikul 
et al., 1992a; Opartkiattikul et al., 1992b). 
Several etiologic factors are thought to play a role in the pathogenesis of the hypercoagulable 
state in thalassemia. Specific changes in the lipid membrane composition of the abnormal 
thalassemic RBCs and the effect of hemosiderosis may contribute to the activation of the 
coagulation cascade and the activation of other blood cells, including the platelets, mono-
cytes, granulocytes and the vascular endothelium, which affect the thrombotic process (Eldor 
and Rachmilewitz, 2002).  Moreover, RBCs of thalassemic patients express higher levels of 
reactive oxygen species and lower levels of intracellular glutathione than do normal eryth-
rocytes, which could be attributed to continuous exposure to oxidative injuries (Visudhiphan 
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et al., 1994).  This leads to the expression of surface anionic phospholipids such as phospha-
tidylethanolamine (PEA) and phosphatidylserine (PS), and a loss in the cell membrane asym-
metry (Manfre et al., 1999).  RBCs of patients with β-TM and TI showed enhanced adhesion 
to cultured endothelial cells (Hovav et al., 1999).  They also, were noticed to facilitate throm-
bin formation (Eldor et al., 1999) and, subsequently, platelets activation in vivo (Ruf et al., 
1997).  RBCs expressing PS may also contribute directly to the vascular damage observed 
in thalassemia patients (Manodori et al., 2000).  On the other hand, RBCs of β-TM and TI 
patients showed increased amounts of membrane-bound hemichromes and immunoglobu-
lins.  In addition, band 3 protein showed oxidative modifications such as aggregation and a 
decrease in the sulfhydryl groups (Cappellini et al., 1999; Mannu et al., 1995). 
Studies of the coagulation proteins provided strong evidences for the existence of a chronic 
hypercoagulable state in thalassemia (Michaeli et al., 1992).  Many reports recorded changes 
in the levels of coagulation factors, coagulation factor inhibitors, and components of the 
fibrinolytic system.  Low levels of protein C and protein S have been observed in patients 
with β thalassemia from a variety of ethnic backgrounds (Cappellini et al., 2000; Shirahata 
et al., 1992).  In Israeli patients, mostly of Kurdish Jewish, Yemenite Jewish or Arabic origin, 
protein C (antigen and activity) and free protein S were significantly decreased in both adults 
and children (Eldor et al., 1999).  Similar results were obtained in studies of TI patients in 
Italy (van Teunenbroek et al., 1989). 
Currently, it is assumed that the mentioned defects and abnormalities could explain many 
clinical observations that patients with TI show.  Venous thrombosis is more prevalent in TI 
patients who are not receiving regular transfusions and have undergone splenectomy 
(Cappellini et al., 2000; Deo et al., 1994).  These patients may be more susceptible to throm-
boembolism because they have more circulating platelets and damaged RBCs.  It was no-
ticed that thalassemic patients in less developed countries who have limited transfusion re-
sources showed more thromboembolic manifestations than those in developed countries.  
This was explained by, having  normal (transfused) RBCs decreases abnormal aggregations 
observed in thalassemic RBCs, which indicates beneficial role of regular blood transfusions 
for those patients (Chen et al., 1996). 
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1.3 Literature review 
Many studies have investigated the correlation between thrombotic manifestations and β- 
thalassemia major and intermedia.  In a multicenter study in Italy involving nine Italian pe-
diatric thalassemia centers, thromboembolism was investigated in patients with β-TM and 
TI.  The incidence of thromboembolic events was lower (3.95%) in β-TM patients than TI 
patients (9.61%)  (Borgna Pignatti et al., 1998).  The same group reported a lower incidence 
(1.1%) of thromboembolic complications among β-TM patients whom were followed for 37 
years (Borgna-Pignatti et al., 2004).  In another study, also in Italy, the prevalence of throm-
boembolic events was 3.3% among β-TM patients compared to 16.2% among TI patients, 
although 15.3% of these patients (i.e. β-TM and TI) had predisposing congenital or acquired 
factors contributing to the hypercoagulability (Moratelli et al., 1998).  Another group fol-
lowed 83 TI patients for 10 years for the incidence of venous thromboembolic events 
(VTEs); pulmonary embolism, DVT, or portal vein thrombosis developed in 29% of them, 
and recurrent VTEs occurred all splenectomized patients (Cappellini et al., 2000).  In a com-
prehensive study, included 8,860 thalassemia patients (6,670 β-TM and 2,190 TI) in the 
Mediterranean region (Lebanon, Italy, Israel, Greece, Egypt, Jordan and Saudi Arabia) in 
addition to Iran, showed 1.65% prevalence of various thrombotic events; which is 4.38 times 
more frequent in TI than β-TM patients (i.e. 0.9% in β-TM and 4.0% in TI).  Furthermore, 
venous events were more frequent in TI, while arterial events were more frequent in β-TM 
(Taher et al., 2006b). 
A study in Italy examined thrombotic mutations in 580 patients with β-TM.  Thirty-three 
were with history of one or more thrombotic episodes, and 29 were splenectomized.  Their 
mean Hb level was (9.07 + 0.3 g/dL) and their mean transfusional interval was (22 + 3 days).  
The tested mutations were FV Leiden (G1691A), FII (G20210A), MTHFR (C677T), GP 
(αIIbβ3) (C1565T) and FVII 4 hyper-variable region (HPVR).  No significant differences 
between the thrombotic thalassemic group and the control group for all analyzed polymor-
phisms were detected except the FVII polymorphism (Iolascon et al., 2001). 
A case study article was published in 2004 about a Lebanese patient with S/β° that suffered 
from pain in the bilateral shoulder and left knee areas.  The case was diagnosed initially to 
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have sickle cell crisis, but duplex scanning revealed a DVT case.  The patient showed ho-
mozygousity for FV Leiden and heterozygousity for MTHFR mutation.  The patient, then, 
was treated with warfarin and did well (Otrock et al., 2005). 
In another study a 24-year-old man with β-TM who expressed three recurrent thrombosis in 
a short time interval, the first was at the age of 19, so, he was treated on low molecular 
weight heparin (LMWH) followed by long-term oral anticoagulant with a target Interna-
tional Normalized Ratio (INR) of 2.5.  At the age of 22, a DVT of the left popliteal vein 
occurred.  Then the INR was decided to be increased from 2.5 to 3.5, so, no other thrombotic 
event occurred until the article date.  The patient had double heterozygosity for FV Leiden 
and FII G20210A mutations, which led the authors to suggest that thalassemia patients 
should be screened for acquired and congenital thrombophilia (Kahn et al., 2002). 
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1.4 Problem statement 
The prevalence of the selected gene mutations that could be associated with hereditary 
thrombophilia including FV Leiden, MTHFR C677T, FII G20210A and platelet GP (β3) 
T1565C polymorphism among thalassemia intermedia patients in the West Bank–Palestine, 
is not known.  The incidence of thrombotic manifestations among thalassemia intermedia 
patients in the West Bank, Palestine and their correlation to genetic thrombotic mutations is 
not known. 
1.5 Goals 
1. Investigating the prevalence of thrombosis among Palestinian TI patients in the West 
Bank.   
2. Determine the prevalence of the indicated gene mutations (FV Leiden, MTHFR C677T, 
FII G20210A and platelet GP (β3) T1565C) among the thalassemia intermedia patients 
in the West Bank-Palestine. 
3. Increasing the awareness against thromboembolic events and their manifestations in tha-
lassemic patients, especially, those who are positive for those mutations and to take care 
of the environmental risk factors for these patients. 
1.6 Justification 
 The prevalence of β- thalassemia trait among the Palestinian population is reasonable to 
some extant; and the prevalence of the trait type among Palestinian population is istimated 
to be 3.5% (Darwish et al., 2005).  One of the manifestations of β-thalassemia, especially 
intermedia, the tendency to have severe thromboembolic manifestations, so screening them 
for those mutations may serve as a first step in reducing the risk of having thrombosis in 
future.  
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1.7 Questions 
Our raised questions are: 
1. What is the frequency of the thrombotic genetic mutations (FV Leiden, MTHFR C677T, 
FII G20210A and platelet GP (β3) T1565C) mutations among TI patients in the West 
Bank-Palestine? 
2. What is the frequency of the thrombotic manifestations among TI patients in the West 
Bank-Palestine? 
1.8 Hypothesis 
Two hypotheses were presented; one of them will be proven and the other will be rejected; 
the null hypothesis (H0) will be returned if no correlation was confirmed between having 
thalassemia intermedia and having one of the tested polymorphisms.  On the other hand, the 
alternative hypothesis (H1) will be retained if the H0 was rejected.
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Chapter Two: Methodology 
_________________________________________________________________________ 
2 Methodology 
2.1 Materials 
Table (2.1) lists all materials that were used in the study. 
Table 2.1: List of materials and instruments used in the study. 
Disposables 
Item Manufacturer/country 
EDTA tubes Greiner bio-one. UK 
Needles Medi-Plus. China 
Syringes Medi-Plus. China 
Chemicals and kits 
Item Manufacturer/country 
DNA extraction kits from blood 
MasterPure™ DNA Purification Kit for Blood Ver-
sion II, Epicentre, USA 
lyophilized PCR master mix 
AccuPower® HotSart PCR PreMix, BIONEER, Ko-
rea 
HinfI NEW ENGLAND BioLabs. UK 
MspI NEW ENGLAND BioLabs. UK 
HindIII NEW ENGLAND BioLabs. UK 
50 bp leader marker GeneDirex 
TRIS base MP Biomedicals. USA 
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Chemicals and kits 
Item Manufacturer/country 
EDTA-Na bi-basic AVONCHEM Ltd. UK 
Agarose Hy.labs. Israel 
Ethidium bromide Hy.labs. Israel 
Machines and instruments 
Item Manufacturer/country 
Thermal cycler Esco Healthcare Ltd. USA 
Nano-drop machine Thermo Scientific. USA 
Gel electrophoresis system Scie-Plas. UK 
Gel documentation system BIO-RAD GEL DOC 2000®, USA 
 
The sequence of the PCR primers are shown in Table (2.2).  All PCR primers were obtained 
from Metabion (Germany).   
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Table 2.2: PCR primers used in this study. 
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2.2 Methods 
2.2.1. Study subjects: 
Our target group was all thalassemia intermedia patients throughout the West Bank – Pales-
tine.  List of the patients’ names and contact informations were obtained from the patients’ 
registration files at the TPFS – Palestine and the clinical care centers that are supervised by 
the Ministry Of Health.  Then, patients were interviewed to fill a questionnaire and to obtain 
a blood specimen.  The inclusion criteria were: presentation of the disease after 2 years of 
birth with fetal hemoglobin (Hb F) level (10 - 50%) (Table 1.3).  Information concerning 
disease onset and Hb F level were obtained from the patient files.  Patients who refused to 
participate or could not be reached were cancelled. 
A matched group from apparently normal individuals (i.e. normocytic normochromic, Hb > 
12.0 g/dL for females and ≥ 13.5 g/dL for males) was collected from the same geographical 
places where patients’ samples were collected, and were used as a control group. 
2.2.2. Questionnaire and consent form: 
An interview-based questionnaire was developed for this study (Appendix A).  The ques-
tionnaire was designed to collect information about the demographic information and med-
ical history of the patient.  Patients were contacted by telephone, invited for participation in 
the study and if they accepted the invitation, they were invited for a personal interview at the 
nearest clinical care center.  During the interview, patients were asked to provide the infor-
mation needed to complete the questionnaire.  After that, they were asked to donate a blood 
sample and to provide a written consent, and those who were younger than 18 years were 
accompanied by their guardian and the guardian was asked to sign a consent form.  
2.2.3. Specimen collection, transporting and preservation: 
One to three milliliters of venous blood was collected in a K3EDTA tubes from each patient.  
Specimens were transported from the blood collection site to the lab at Al- Quds university; 
where they were processed within one week of collection.  Specimens were transported in a 
temperature-insulating box and kept at 6 + 2°C from the time of specimen collection until 
the preparation of genomic DNA. 
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2.2.4. Preparation of genomic DNA: 
Genomic DNA was prepared from the buffy coat using a commercially available kit (Mas-
terPure™ DNA Purification Kit for Blood Version II, Epicentre, USA).  Briefly, whole 
blood was centrifuged at 3,500 x g for 3 – 5 minutes.  Then, 600 µL of the buffy coat were 
transferred into a 1.5 mL tube, mixed well, and separated into two equal portions.  This was 
followed by the addition of 1.2 mL Red Cell Lysis (RCL) buffer to each tube in order to lyse 
the RBCs.  The tubes were, then, mixed by inversion three times with flicking the bottom of 
the tubes; in order to re-suspend the WBCs.  Then, the mixture was incubated at room tem-
perature for 10 minutes with shaking every 5 minutes.  After that, precipitation of the WBCs 
was achieved by centrifugation at 10,000 × g for 25 seconds.  This, usually, resulted in a 
small white pellet that settled underneath a clear reddish supernatant, indicating a good RBC 
lysis step.  If the supernatant was not clear or the pellet contained a reasonable amount of 
intact RBCs, the RBC lysis step was repeated by adding additional RCL buffer.  The super-
natant was discarded and the pellet was re-suspended in about 25 µL of the left over. Then, 
the WBCs were lysed by emulsifying the cells in 600 µL of the Tissue and Cell Lysis (TCL) 
solution.  The highly viscous solution was pipetted several times in order to insure complete 
cell lysis.  The next step was the protein precipitation step; that was achieved by salting out  
and involved the addition of 250 µL of the MPC solution (a highly concentrated; 6M, NaCl 
aqueous solution) followed by vigorous shaking of the solution for 15 – 30 seconds.  After 
that, clear clumps would appear indicating the success of the protein salting out process.  
Retaining a clear DNA solution and getting rid of the protein debris was achieved by cen-
trifugation at 10,000 × g for 10 min.  Then, the supernatant was transferred into a new 1.5 
mL tube and the former tube was discarded.  For precipitation of the DNA from the solution, 
about two volumes (i.e. 700 µL) of absolute isopropanol were added to each tube, then, tubes 
were inverted 30 – 40 times.  The sample was centrifuged at 10,000 x g for 10 minutes, then, 
the supernatant was discarded and the pellet was rinsed with 500 µL of 70% ethanol and the 
pellet was left on (40 °C) in order to get rid of the volatile alcohol.  Finally, hydration of the 
DNA was done by the addition of 100 µL of 1/2 TE buffer with pH 7.5, and the DNA solution 
was preserved at -20°C and later used for DNA amplification. 
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2.2.5. Assessment of DNA concentration and purity: 
Assessment of the DNA concentration and purity were determined spectrophotometrically 
by the NanoDrop 2000 Spectrophotometer (Thermo Fisher Scientific®).  Purity and DNA 
concentration were assessed by measuring the optical densities A260, A280, A230.  Samples 
that gave A260/280 ratio greater than (1.8) indicating a good purity and minimum protein in-
terferences of the DNA preparation were used for PCR amplification.  All samples gave 
A260/230 ratio greater than (2.0); which infers acceptable salt interferences.  All preparations 
gave higher concentrations than (100 µg/mL); and those with very high concentrations were 
diluted to (100 µg/mL). 
2.2.6. Mutation analysis: 
The FVL G1691A, FII G20210A (Huber et al., 2000), MTHFR C677T (Frosst et al., 1995) 
and GP β3 T1565C (Pellitero et al., 2010) mutations were analyzed by restriction fragment 
length polymorphism polymerase chain reaction (RFLP-PCR) technique as described ear-
lier.  The sequence of PCR primers and PCR amplicon size are shown in Table (2.3).  How-
ever, the amplification of the FII G20210A fragment was modified by designing a new for-
ward primer to shorten the PCR amplicon to 264 bp, and thus the products of HindIII re-
striction digestion (232 bp for mutant amplicon and 264 bp for normal/ wild type amplicon) 
are easily resolved by agarose gel electrophoresis, compared to the primer pair described 
earlier (Huber et al., 2000); that produces an amplicon of 506 bp.  This amplicon gives 384bp 
product for mutant amplicon and 407 bp for normal/ wild type amplicon upon digestion with 
HindIII, which are poorly resolved by agarose gel electrophoresis.  
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Table 2.3: Primers and mutations’ detection parameters. 
 The amplification of the GP β3 gene we the step – down way for primer annealing temperature  
was used; where 56 oC was used for 15 cycles followed by 20 cycles at 55 oC. 
  
Mutation 
Annealing 
Temp. 
(°C) 
PCR 
amplicon 
(bp) 
 R
es
tr
ic
ti
o
n
 
 E
n
zy
m
e 
Restriction 
Products (bp) References 
Normal Mutant 
FVL 
(G1691A) 
55 241 HindIII 241 
209 
+ 32 
(Huber et al., 2000) 
FII 
(G20210A) 
55 264 HindIII 264 
232 
+ 32 
Modified from 
(Huber et al., 2000) 
MTHFR 
(C677T) 
56 198 HinfI 198 
175 
+ 23 
(Frosst et al., 1995) 
GP β3 
(T1565C) 
56 
& 55* 
266 MspI 
221 
+ 45 
177 
+ 44 + 
45 
(Pellitero et al., 2010) 
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2.2.6.1. Gene Amplification: 
Gene amplification was achieved by Polymerase Chain Reaction (PCR) technique, where 
lyophilized master mix kit (AccuPower® HotSart PCR PreMix, BIONEER, Korea) was 
used.  The PCR master mix contained a lyophilized mixture of Hot-start Taq DNA Polymer-
ase, Buffer, MgSO4, dNTPs and the loading buffer.  Primers and DNA samples as well as 
the nuclease-free water were added to the mix (Table 2.4).  The PCR components were 
mixed in the provided (0.2 mL) test tubes and the reactions were run using a thermal cycler 
(Esco Healthcare Ltd. USA) was used. Thermal cycling programs and the annealing temper-
atures of the primers are shown in Table (2.5).   
 
Table 2.4: Components of PCR reaction. 
Reaction component Volume (µL) 
Lyophilized master mix 0 
DNA sample (100 µg/mL) 3 
Forward Primer (10µM) 0.5 
Reverse Primer (10 µM) 0.5 
DEPC- Water 16 
Total Volume 20 
 
Table 2.5: Programs used for gene amplification. 
Step Duration Temperature (°C) 
Initial denaturation 5 min. 94 
35 cycles: 
Denaturation 
Annealing 
Extension 
 
30 sec. 
30 sec. 
1min. 
 
94 
55 or 56* 
72 
Final extension  5 min. 72 
*An annealing temperature of (55 °C) was used for FVL and FII G20210A, and (56 °C) for the 
MTHFR.  A step down annealing temperature was used for the GP β3; (56 °C) for 15 cycles fol-
lowed by (55 °C) for 20 cycles. 
 
 
The PCR products were analyzed by running 5 µL of the PCR product on 3% agarose gel at 
100 Volts and the band in question was detected according to Table (2.3).  
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2.2.6.2. Restriction Digestions: 
Samples that gave the expected PCR amplicon in the previous section were further subjected 
to restriction digestion with the appropriate restriction enzyme as shown in Table 2.6).  All 
restriction reactions were incubated at 37°C for at least 4 hours (Table 2.6).  All restriction 
enzymes were obtained from New England BioLabs®, UK.  
 
Table 2.6: Components of the restriction digestion reaction of PCR amplicons. 
Reaction component Volume (µL) 
PCR product 10 
Restriction Enzyme (2000 U) 0.3 
Buffer 2 
Purified Water 7.7 
Total Volume 20 
 
The entire product of the restriction digestion (about 20 µL) was run on a 3% agarose gel at 
100 V for about 45 minutes, or until the DNA fragments are resolved.  After that, the gel 
was viewed and photographed using a gel documentation system (BIO-RAD GEL DOC 
2000®, USA) in order to detect and discriminate between normal, heterozygous and homo-
zygous  bands (Table 2.3). 
2.2.7. Data analysis: 
Data were analyzed using two softwares; Microsoft Excel 2013® and SPSS 17®.  Drawing 
tables and building figures were executed using the Excel, while the association analyses 
were done using the SPSS.  The test for association was used to test the significance of the 
relationships between the variables was the Chi-square, and a p-value less than 0.05 was 
considered significant. 
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Chapter Three: Results 
_________________________________________________________________________ 
3 Results 
3.1 Study population  
The exact number of thalassemia patients or their classifications into major, intermedia or 
minor is not precisely known in Palestine.  A patient who is registered in one health care 
center is not necessarily registered in the TPFS, and vice versa.  Therefore, the registration 
files of those patients are not identical between the two sources that cooperated with us; 
TPFS and the health care clinics that are subordinated by the Ministry of Health.  Many files 
did not contain any information about the medical history or diagnosis of the patient, except 
his/her personal information.  Some patients were classified as β-TM in some files while 
others considered them as TI.  Therefore, we went over the files and made our classification 
according to the criteria mentioned in Table (1.3), and those who met the TI criteria were 
included in the study. 
One hundred forty-eight patients have fulfilled the criteria of TI and thus were approached 
to participate in this study.  Then we tried to reach all of them by phone, but many refused 
to participate or didn’t attend on the assigned dates to meet them at the health care center 
close to his/her residence place.  In total, we have succeeded to recruit 82 TI patients.  These 
82 patients provided all the information needed to complete the study questionnaire and do-
nated blood samples for the study.  In Hebron there was a good response from TI patients 
compared to other cities, where 48 out of the 65 TI patients participated in this study.  The 
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lowest response was in Ramallah; where 10 out of the 48 TI patients (21%) were included 
in the study.  This low rate of participation observed among TI patients from Ramallah can 
be attributed to several factors.  Three of the 38 patients, who were not included in this study, 
couldn’t be reached neither by phone nor by a specific address, moreover, they didn’t follow 
their medication for several years.  Thirteen patients were residing abroad during the period 
of the study (10 in the United States of America and 3 in Jordan), three refused to participate, 
one was in the Israeli prison and the rest promised to participate but they didn’t come on the 
assigned dates.  Finally, five TI patients were registered in Jenin and all of them participated 
in this study. 
Table (3.1) shows the distribution of all TI patients registered at the TPFS and the clinical 
care centers among cities of West Bank, as well as the distribution control group.  This clas-
sification is consistent with their residence place in most cases with some exceptions; where 
some patients are registered in a health care center (or a branch of the TPFS) and are resident 
at a different place. 
Table 3.1: Distribution of TI patients among the different cities in the West Bank region. 
Thalassemia 
Care Centers 
Patients 
Control  
subjects No. registered 
No. participated in this 
study 
Hebron 65 48 48 
Ramallah 48 10 10 
Nablus 20 12 12 
Tulkarm 10 7 7 
Jenin 5 5 5 
Total 148 82 82 
 
The highest proportion of the thalassemia intermedia cases in the West Bank was reported 
in Hebron (44%), while the lowest number of cases was reported in Jenin (3.4%) (Table 3.1).  
However, the number of patients reported in each city showed a gradual decline from the 
south to the north (Figure 3.1 and Table 3.1). 
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About 55% (82 of 148) of the whole registered patients were included in our study; with a 
highest response from Jenin area (100%), but with the lowest percentage was from Ramallah 
(21%).  However, the highest number of thalassemia intermedia participants who responded 
to the study was from the Governmental Hospital of Hebron (representing 58% of study 
samples).  Patients from the northern area; Jenin, Tulkarm and Nablus composed 6%, 9% 
and 15% of the total study sample, respectively.  While patients from Ramallah represented 
12% of the total study samples (Figure 3.2). 
 
 
 
 
 
 
 
Hebron, 
58%
Ramallah, 12%
Nablus, 
15%
Tulkarm, 
9% Jenin, 6%
Distribution of tested sample relative to the 
total 
Figure 3.2: Distribution of TI patients who participiated in this study 
according to their residence place. 
Figure 3.1: Distribution of thalassemia intermedia patients among the different care 
centers / cities in West Bank. 
Hebron
44%
Ramallah
32%
Nablus
14%
Tulkarm
7%
Jenin; 3%
Distribution of the patients in registers
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3.2 Genetic thrombotic mutations 
FII (G20210A) polymorphism was detected by RFLP-PCR.  The PCR product was digested 
with HindIII enzyme and analyzed by agarose gel electrophoresis.  A 264 bp fragment indi-
cates normal allele while detection of 232 bp plus 32 bp (this small fragment was not de-
tected on agarose gel) indicates the presence of a mutant allele (Figure 3.3). 
 
 
 
 
 
 
 
FVL (G1691A) mutation was detected by RFLP-PCR.  The PCR product was digested with 
HindIII enzyme and analyzed by agarose gel electrophoresis.  Detection of a 241 bp fragment 
indicates normal allele while detection of 209 bp plus 32 bp (this small fragment was not 
detected on agarose gel) indicates the presence of a mutated allele (Figure 3.4). 
Figure 3.3: FII (G20210A) polymorphism pattern. 
M: 50 bp DNA ladder.  (-/-) Normal (N).  (+/+) Homozygous mutant (H).  (+/-) Heterozygous 
(R).  Samples 1, 3, 4, 6, 7 and 8 are normal, samples 2 and 5 are heterozygous. 
         +/+    +/-      -/- 
200 bp 
232 bp 
264 bp 
  M       H        R       N        1       2       3       4        5        6       7       8       M 
Figure 3.4: FVL (G1691A) mutation pattern. 
M: 50 bp DNA ladder.  (-/-) Normal (N).  (+/+) Homozygous mutant (H).  (+/-) Heterozy-
gous (R).  Samples 1, 3, 5, 7 and 8 are normal, samples 2 and 4 are heterozygous. 
           +/-    +/+    -/- 
200 bp 
 M                          R      H      N      1       2       3      4        5       6      7     M 
209 bp 
241 bp 
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The MTHFR (C677T) mutation was detected using RFLP-PCR.  The PCR product was di-
gested with HinfI.  Analysis of HinfI restriction fragments by agarose gel revealed 198 bp 
fragment for the wild type or normal allele, and 175 bp and 23 bp fragments for the mutant 
allele (Figure 3.5).  
 
 
 
 
 
 
 
The GP (β3) T1565C mutation was detected by RFLP-PCR.  The PCR product was digested 
with MspI.  Agarose gel electrophoresis of the MspI restriction fragments showed a 221 and 
45 bp fragments for the wild type allele or T allele, and 175, 44 and 45 bp fragments fo the 
mutant or the C allele (Figure 3.6). 
 
 
 
 
 
 
 
Figure 3.5: MTHFR C677T polymorphism pattern. 
M: 50 bp DNA ladder.  (-/-) Normal (N).  (+/+) Homozygous mutant (H).  (+/-) Hetero-
zygous (R).  Samples 1, 2, 5, 8, 10 and 11 are heterozygous, samples 3, 4 and 7 are normal, 
and samples 6 and 9 are homozygous mutant. 
200 bp 
198 bp 
175 bp 
   M      N      R       H      1      2       3      4       5     6       7      8       9     10    11    M 
           -/-    +/-    +/+ 
Figure 3.6: GP (β3) T1565C mutation pattern. 
M: 50 bp DNA ladder.  (-/-) Normal (N).  (+/+) Homozygous mutant (M).  (+/-) Heterozygous 
(R).  Samples 1, 2, 4, 7, 8, 10 and 11 are normal, samples 3, 5 and 6 are heterozygous and sample 
9 is homozygous mutant. 
200 bp 
177 bp 
221 bp 
+/-   -/-    +/+    
   M      1      2      3      4      5      6      7      8      9      10    11     R     N      H    M   
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The frequencies of thrombotic mutations among the study group are summarized in Table 
(3.2).  Each genotype was categorized into three sub groups; wild type (or normal, N), het-
erozygous (R) and homozygous mutant (H).  The frequencies of each genotype analyzed are 
show in Table 3.2 Table (3.2).  For each mutation, eventually, allele frequency was set ac-
cording to the relative occurrence of each allele in each sample population (i.e. wild type or 
mutated).  The purpose of doing this type of grouping is to assess the frequency of each allele 
among the study subjects. 
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Table 3.2: Prevalence of thrombogenic mutations in thalassemia intermedia patients and in the normal control group. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Pt: Patients. Nc: Normal controls. N: Normal (wild type polymorphism). R: Heterozygous. M: Homozygous. FII: Thrombin.  
FVL: Factor V Leiden.  MTHFR: Methylene Tetrahydropholate Reductase.  GP β3: Glycoprotein (β3) subunit.
District Pt/Nc (n) 
FII 
(G20210A) 
FVL 
(G1691A) 
MTHFR 
(C677T) 
GP β3 
(T1565C) 
N R H N R H N R H N R H 
Hebron 
Pt (48) 46 0 2 39 9 0 22 23 3 46 2 0 
Nc (48) 47 1 0 38 10 0 21 23 4 37 11 0 
Ramallah 
Pt (10) 10 0 0 6 4 0 7 1 2 8 2 0 
Nc (10) 10 0 0 8 2 0 2 7 1 8 2 0 
Nablus 
Pt (12) 11 1 0 11 1 0 11 1 0 9 2 1 
Nc (12) 11 1 0 8 4 0 5 6 1 7 4 1 
Jenin 
Pt (5) 5 0 0 3 2 0 3 2 0 3 2 0 
Nc (5) 5 0 0 4 1 0 4 1 0 3 2 0 
Tulkarm 
Pt (7) 7 0 0 7 0 0 2 5 0 7 0 0 
Nc (7) 7 0 0 3 4 0 1 5 1 7 0 0 
Total 
Pt (82) 
(%) 
79 
(96.2) 
1 
(1.3) 
2 
(2.5) 
66 
(80.5) 
16 
(19.5) 
0 
(0) 
45 
(54.9) 
32 
(39.0) 
5 
(6.1) 
73 
(89.0) 
8 
(9.8) 
1 
(1.2) 
Nc (82) 
(%) 
80 
(97.5) 
2 
(2.5) 
0 
(0.0) 
61 
(74.4) 
21 
(25.6) 
0 
(0.0) 
33 
(40.2) 
42 
(51.3) 
7 
(8.5) 
62 
(75.6) 
19 
(23.2) 
1 
(1.2) 
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Homozygosity for FII (G20210A) polymorphism was detected in two patients from Hebron, 
and those were the only homozygous cases that were detected in the study (Table 3.2).  None 
of the normal group were homozygous for the FII polymorphism. 
Sixteen TI patients (19.5%) and 21 (25.6%) subjects of the normal control group showed 
heterozygosity for FVL, while no case showed homozygosity in both groups.  Moreover, the 
results showed dominancy of the FVL mutation in the southern area (i.e. Hebron); where 
about (11.0%) of the patient and (13.4%) of the normal group were positive for the FVL 
mutation, respectively (Table 3.2). 
Analysis of the data showed that 32 (39%) of the TI patients were heterozygous and 5 pa-
tients (6.1%) were homozygous for the MTHFR C677T mutation (Table 3.2), compared to 
42 subjects (51.3%) of the control group were heterozygous and 7 subjects (8.5%) were 
homozygous for MTHFR C677T mutation (Table 3.2).  The frequency of MTHFR C677T 
mutation was the highest in this study compared to the other 3 mutations / polymorphisms 
analyzed (Table 3.2).  Hebron contained the highest frequency of MTHFR C677T polymor-
phism (54% and 65%) for the patients and the normal groups, respectively. 
Analysis of the results showed that eight cases were heterozygous and one case was homo-
zygous mutant for the GP (β3) T1565C mutation among the IT patients.  While 19 cases 
were heterozygous and one case was homozygous mutant for the GP (β3) T1565C mutation 
among the normal control group (Table 3.2). 
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The frequency of the four mutations / polymorphisms was, also, tested in different way, by 
calculating the frequency of mutated allele in the population (Table 3.3).   
Table 3.3: Frequency of the mutant and normal alleles among the study populations 
 
FII 
(G20210A) 
FVL 
(G1691A) 
MTHFR 
(C677T) 
GP β3 
(T1565C) p- value 
G A G A C T T C 
Pt 
(n) 159 5 148 16 122 42 154  10  
0.05 
(%) (97.0) (3.0) (90) (10) (74.4) (25.6) (93.9) (6.1) 
NC 
(n) 162 2 143 21 108 56 143 21 
(%) (98.8) 1.2)  (87) (13)  (65.9)  (34.1)  (87.2)  (12.8) 
Pt: patients, Nc: normal control group. 
The total number of the alleles of the four mutations / polymorphisms for the 82 TI patients 
is 164, and gives the same for the normal control group. 
FII mutant allele (G20210A) or A allele was found in 5 out of 164 chromosomes (about 3%) 
of the TI patients and in 2 out of 164 chromosomes (about 1.2%) of the normal control 
subjects (Table 3.3).  This showed that the frequency of the A allele is rare among the TI 
patients (3%) as well as among the normal control subjects (1.2%).  
Analysis of the FVL allele (A allele) among the study population revealed that the FVL 
allele was found in 16 out of 164 chromosomes (about 10%)  of the TI patients and in 21 out 
of 164 chromosomes (about 13%) of the normal control group (Table 3.3).  Statistical anal-
ysis using Chi-square test of the difference of A allele frequency between IT patients and 
normal control group showed no significant difference.  
The frequency of the T allele of MTHFR was observed in 42 out of 164 chromosomes 
(25.6%) among the TI patients compared to 56 out of 164 chromosomes (34.1%) in the nor-
mal control group (Table 3.3).  Statistical analysis showed no significant difference between 
the frequency of MTHFR alleles between TI patients and normal control group (Table 3.3). 
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3.3 Acquired thrombotic risk factors 
Information about the acquired risk factors were obtained from patients’ files and the ques-
tionnaire filled by direct contact with them before sample collection. 
The acquired risk factors analyzed here included previous thrombotic manifestations, sur-
gery (including splenectomy), prolonged immobilization, pregnancy, oral contraceptives ad-
ministration and smoking (Table 3.4).  These factors can predispose patients to thrombosis.  
Three out of the 82 TI patients suffered from thrombotic manifestations at least once in 
his/her life.  Twenty-six out of the 82 patients under went at least one surgical operation, 
twenty-three of them underwent splenectomy.  Four women gave births (ranged from 1 to 
12 births).  The frequency of the other screened risk factors are listed below (Table 3.4). 
Table 3.4: Prevalence of acquired risk factors among Thalassemia intermedia patients vs. fre-
quency of heterozygosity among patients. 
Acquired Risk Factors Number of cases 
 Total 
Thrombotic manifestations 3 
Surgery  
Splenectomy 
Splenectomy and other surgeries 
Other than splenectomy 
26 
23 
 
14 
Prolong immobilization 1 
Pregnancy 4 
Oral contraceptives  1 
Smoking 7 
Hz: heterozygous for one mutation, DHz: doubled heterozygous, THz: tripled heterozygous, QHz: 
quadrupled heterozygous.  
Since it has been shown that splenectomy contributes to hypercoagulability (Cappellini et 
al., 2005; Eldor and Rachmilewitz, 2002), patients were subcategorized into splenectomized 
(Sp.) and nonsplenectomized (NSp.) groups (Table 3.5) to investigate the effect of throm-
botic genetic mutations on splenectomy.  Chi-square analysis of the frequency of thrombotic 
mutations revealed no statistically significant difference between splenectomized and 
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nonsplenectomized, as well as between nonsplenectomized patients and normal control 
group (Table 3.5). 
Table 3.5: Frequency of the mutant and normal genes among the study populations. 
Sp: splenectomized, NSp: nonsplenectomized, NCs: Normal controls. 
 
 
The frequency of the FII G20210A mutation was more prevalent in nonsplenectomized pa-
tients (5.1%) than that in the normal controls (2.4%), and all the nonsplenectomized patients 
were free of the mutation.  Comparable results were obtained for the FVL mutation between 
splenectomized patients (26.1%) and normal controls (25.6%).  In addition, relatively, com-
parable results were obtained for the MTHFR C677T mutation among splenectomized pa-
tients (39.1%), nonsplenectomized patients (49.2%) and normal controls (40.2%). 
However, results of the GP β3 T1565C polymorphism showed higher frequency in the nor-
mal control group than the TI patients groups, either whom undergone splenectomy (17.4%) 
or the nonsplenectomized patients (6.8%). 
 
FII 
(G20210A) 
FVL 
(G1691A) 
MTHFR 
(C677T) 
GP β3 
(T1565C) 
N M N M N M N M 
NSp. Pts. 
(59) 56 3 49 10 30 29 55 4 
(%) 94.9 5.1 83.1 16.9 50.8 49.2 93.2 6.8 
Sp. Pts. 
(23) 23 0 17 6 14 9 19 4 
(%) 100 0.0 73.9 26.1 60.9 39.1 82.6 17.4 
NCs. 
(82) 80 1 61 21 33 49 63 19 
(%) 97.6 2.4 74.4 25.6 40.2 59.8 76.8 23.2 
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Chapter Four: Discussion 
_________________________________________________________________________ 
4 Discussion 
Analysis of the frequency of TI patients among the different cities showed a gradual increase 
in the incidence of reporting of TI cases from north to south; where Hebron encountered the 
highest incidence (65 patients out of 148)  and Jenin the lowest (5 cases out of 148).  Alt-
hough Hebron has the highest number of population among all cities of West bank, but other 
factors could also contribute to this finding such as the high rate of consanguinity, which is 
more prevalent in the southern area.  In support of the later argument and upon analysis of 
the family names of TI from Hebron, it was observed that 14 patients were from one family 
and another 11 patients were from another family, although not all of these cases participated 
in this study.  However, since an accurate estimation of the number of TI cases in Palestine 
is not available, this makes it difficult for us to judge on how much our study sample is 
representative of the TI population. Additionally, since the clinical severity of thalassemia 
intermedia varies widely, many patients may be not well diagnosed and the number of TI 
patients most probably is underestimated. 
Our results revealed that 3 out of the 82 TI patients (3.7%) experienced at least one throm-
botic manifestation throughout their lives.  This result matches the results of some earlier 
international studies and disagrees with others; especially those that surveyed Mediterranean 
populations for a correlation between TI and tendency towards developing thrombotic man-
ifestations; where Borgna Pignatti et al. (1998) found that the incidence of thromboembolic 
events among 52 Italian TI patients was 9.61%, and Taher et al. (2006b) reported a 4.0% 
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prevalence of various thrombotic events among 2,190 TI patients from the  Mediterranean 
region. 
The frequency of heterozygous and homozygous mutant genotypes among TI patients were 
1.3% and 2.5% for the FII G20210A; 19.5% and 0% for FVL G1691A; 39% and 6.1% for 
MTHFR C677T and 9.8% and 1.2% for the GP β3 C1565T, respectively.  While the fre-
quency of heterozygous and homozygous mutant genotypes among the normal control group 
were 2.5% and 0% for the FII G20210A; 25.6% and 0% for FVL G1691A; 51.3% and 8.5% 
for MTHFR C677T and 23.2% and 1.2% for the GP β3 C1565T, respectively.  Hussein 
(2012) reported the frequency of FVL G1696A, FII G20210A and MTHFR C677T muta-
tions among a cohort of 303 university students from An-Najah University at 20.1%, 9.1% 
and 13.8%, respectively.  Thus, the frequency of FII G20210A reported in this study is lower 
than that reported by Hussein (2012).  But, the frequency of FII G20210A polymorphism 
among the study population was consistent with that reported earlier in other populations 
such as in Danish (2.1% heterozygotes & 0.01% homozygotes; (Weischer et al., 2010), in 
Turkish (3.5% heterozygotes and homozygotes; (Yokus et al., 2009) and in whites (2-3% 
heterozygotes; homozygotes are rare; (Fogerty and Connors, 2009).  The frequency of FVL 
reported here is similar to that reported by Hussein (2012) but the frequency of MTHFR 
C677T reported here is higher than that reported by Hussein (2012).  The difference between 
the two frequencies can be attributed partially to the different sample size, and thus further 
studies are needed to give a more accurate estimate of the frequency of these mutations.  
However, the frequency FVL G1691A and MTHFR C677T mutations among the study pop-
ulation was higher than that reported in other populations (Kujovich, 2011; Yokus et al., 
2009).  Yokus et al. (2009) reported that the frequency of FVL G1691A and MTHFR C677T 
mutations among a population of young adults presenting with thrombosis to be 20% (with 
18% being heterozygotes) and 20.9% (with 10% heterozygotes).  While Kujovich (2011) 
reported that the frequency of FVL G1691A mutation (heterozygotes and homozygotes) 
among several European populations is 3-15%, among Jordanians 12.2% and among Leba-
nese 14%.   
The frequency of mutant alleles of the FII (G20210A), FVL (G1691A), MTHFR (C677T) 
and GP β3 (T1565C) mutations/polymorphisms among the TI patients was 3%, 10%, 25.6% 
and 6.1%, respectively. While the frequency of mutant alleles of the FII (G20210A), FVL 
(G1691A), MTHFR (C677T) and GP β3 (T1565C) mutations / polymorphisms among the 
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normal control group was 1.2%, 21%, 34.1% and 12.8%, respectively. Statistical analysis of 
the difference in frequency of mutant alleles between TI patients and normal control group 
revealed no significant difference in all studied alleles. However, this study included about 
55% of all TI patients (n=148) in the West Bank, and given that the actual number of TI is 
most probably underestimated, so, generalization of these results must be carefully handled. 
In addition, analysis of the correlation between genetic thrombotic mutations analyzed in 
this study and acquired thrombotic risk factors and in particular in patients who have expe-
rienced previous thrombotic manifestations suggest that, at least in these subjects, genetic 
thrombotic mutations may play a role in thrombotic manifestations observed in these pa-
tients.   
In 2005, a study conducted in Palestine among 148 β-thalassemia patients to identify the 
causative β- globin gene mutations.  The most frequent mutations were the IVS-I-6 (T>C), 
IVS-I-110 (G>A), IVS-I-1 (G>A) and codon 37 (G>A) (Darwish et al., 2005).  However, 
patients’ files did not include the molecular diagnosis of the patients, except one case whose 
file contained a positive report for IVS-I-110 (G>A) mutation.  So, more work and efforts 
are needed to improve the diagnosis of thalassemia intermedia patients in Palestine. 
In conclusion, this study reported the frequency of four thrombotic genetic mutations FVL 
G1691A, FII G20210A, MTHFR C677T and GPβ C1565T mutations/polymorphisms, 
among TI patients and a normal control group.  No statistically significant difference was 
observed in the frequency of these mutations between TI patients and normal control group. 
These results indicate that the hypercoagulable state present in our TI patients may not be 
affected by these thrombotic genetic mutations.  Although these mutations / polymorphisms 
may contribute to the hypercoagulable state in TI when present in combination with other 
acquired or environmental risk factors.  Additionally, our results indicate a high frequency 
of three thrombotic genetic mutations namely FVL G1691A, MTHFR C677T and GPβ 
C1565T mutations compared to other populations.  The latter finding warrants further inves-
tigation of these mutations in terms of their clinical significance.
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 الملخص
 لسطينف –لاسيميا المتوسطة في الضفة الغربية ثفرات المسببة للتجلط في مرضى التحديد الط
 
 إعداد الطالب: محمد عصام عبد الفتاح كردي
 مشرف أول: الدكتور محمود عبد الرحمن سرور
 اليونسجا ر  ستاذ خالدالأ مشرف ثاني:
ؤدي كل منها ، يالخضاب (الهيموغلوبين) تؤثر على تصنيعجانسة من الاضطرابات الوراثية الثلاسيميا مجموعة غير مت
 صورةمد عتت . )الهيموغلوبينالخضاب (من الكريين (الغلوبين) انخفاض معدل الإنتاج واحد أو أكثر من سلاسل  ىلإ
تم تصنيف ي الأخرى التي تحدد الصورة السريرية للمريض. المرافقة الخارجية  العواملعلى شدة الطفرة و الناتجة المرض 
)، الثلاسيميا الطفيفة و الثلاسيميا الوسطى MTالعظمى( الثلاسيميا: رئيسيةيا إلى ثلاثة أقسام فرعية الثلاسيميا سرير 
مرضى   .γو β، α: كريينالمن الجينات  أكثرواحد أو نتيجة خلل في عادة الثلاسيميا الوسطى تسبب وت  .)IT(
التي تؤثر على معظم أجهزة الجسم بما في ذلك تشوهات العظام شديدة كثيرة، و يعانون من مضاعفات سريرية الثلاسيميا 
طى أكثر وسالالثلاسيميا مرضى حظت العديد من المضاعفات التي تم تحديدها في و وقد ل  .تضخم الكبد و الطحالو 
نحو تشكيل مضاعفات الانسداد التجلطي الوريدي، بين هذه المضاعفات هو الميل   .من مرضى الثلاسيميا العظمى
 .الرئوي و المخي أو جلطة في أي موقع أخرى من الجسم
الوسطى من منطقة الضفة  هدفت هذه الدراسة إلى تحديد الطفرات الجينية الخثارية في مجموعة من مرضى الثلاسيميا
تزيد من خطر الإصابة بالأعراض التجلطية في هؤلاء المرضى.  و لهذا الغرض تم اللائي قد  الغربية في فلسطين، و
)، A01202G( )، طفرة البروثرومبينA1961Gالبحث عن أربعة طفرات خثارية هي: طفرة العامل الخامس لايدن (
 ).651TC5) (β3الدموية السكري ( و طفرة برتين الصفائح) T776C( هيدروجين الفولاتطفرة مختزل رباعي 
اثنان وثمانون مريضا بالثلاسيميا الوسطى، من مرضى الضفة الغربية تم جمعهم من مراكز رعاية مرضى الثلاسيميا في 
بالإضافة إلى تضمين مجموعة مطابقة من المتطوعين الطبيعيين غير  منطقة الضفة الغربية و تضمينهم في الدراسة. 
تم فحص العينات لوجود  جموعة ضابطة محددة لمجموعة المرضى. المصابين بأي فقر الدم في الدراسة لتستخدم كم
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م تحليل )، و تRCP – PLFRالطفرات الأربعة باستخدام طريقة تعدد أشكال القطع المقطوعة للتفاعل التسلسلي المتعدد (
 .)0...( α النتائج وفقا لمربع كاي
ا الوسطى من الشمال إلى الجنوب؛ حيث كان المعدل الإصابة بالثلاسيمي أظهرت الدراسة زيادة تدريجية في معدل حالات
حالة).  و قد بلغ معدل حدوث مظاهر الجلطات بين  05حالات)، والأعلى في محافظة الخليل ( 0الأدنى في جنين (
الثلاسيميا الوسطى  من مرضى ٪1.3).  وكشفت الاختبارات الجزيئية عن أن ٪3.7الثلاسيميا الوسطى نسبة ( مرضى
وفقا لطفرة العامل الخامس  ). A01202G( كانت متماثلة اللواقح بالنسبة طفرة البروثرومبين ٪ 0.5فرة  و يحملون الط
من المرضى كانوا متخالفي اللواقح، و لم يتم الكشف عن أي حالات متماثلة اللواقح.   ٪ 5.91 )A1961Gلايدن (
من  ٪ 31)؛ حيث أظهر T776Cن الفولات (كانت أعلى نسبة بين الأشكال الأربعة طفرة مختزل رباعي هيدروجي
) β3متماثلي اللواقح.  أما بالنسبة لطفرة برتين الصفائح الدموية السكري ( ٪3.5المرضى تغاير اللواقح، و كان 
من المرضى.  و كشف  ٪5.3من المرضى و متماثلو اللواقح شكلوا  ٪ 9.3) فكانت نسبة متخالفي اللواقح C5651T(
الثلاسيميا  عدم وجود فروق ذات دلالة إحصائية في وتيرة كل من طفرات الأربع بين المرضىتحليل مربع كاي عن 
كن أن المكتسبة يمبالوسطى مقارنة مع المجموعة الضابطة المحددة.  ومع ذلك عندما تقترن مثل هذه العيوب الوراثية 
من  يميا الوسطى، كما تبين في ثلاثةتسهم في حالة الميل نحو فرط الخثورية في المرضى الذين يعانون من الثلاس
) و مرتفعة A01202G( علاوة على ذلك، أظهرت نتائجنا نسبة متدنية لطفرة البروثرومبين . ضمن عينة البحث المرضى
 .) بين الفلسطينيين مقارنة مع التقارير السابقةT776Cبالنسبة لطفرة مختزل رباعي هيدروجين الفولات (
الثلاسيميا الوسطى  في وتيرة كل من طفرات الأربع بين المرضىيلاحظ أي فرق إحصائي م في الختام، لعلى أي حال، 
الثلاسيميا الوسطى  ، فإن هناك حاجة لمزيد من الفحوصات المرضىومع ذلك  .مقارنة مع المجموعة الضابطة المحددة
 ل هؤلاء المرضى.للبحث عن عيوب وراثية خثرية أخرى قد تساعد على تقييم حالة فرط الخثورية في مث
